-
1
-
-
79958043675
-
-
Bethesda, MD: National Cancer Institute. Based on November 2011 SEER data submission, posted to the SEER Web site April, Accessed June 29, 2012
-
Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Altekruse SF, Kosary CL, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Eisner MP, Lewis DR, Chen HS, Feuer EJ, Cronin KA, eds. SEER cancer statistics review, 1975-2009 (vintage 2009 populations), Bethesda, MD: National Cancer Institute. Based on November 2011 SEER data submission, posted to the SEER Web site April 2012. http://seer.cancer.gov/csr/1975 2009 pops09/, Accessed June 29, 2012.
-
(2012)
SEER Cancer Statistics Review, 1975-2009 (vintage 2009 populations)
-
-
Howlader, N.1
Noone, A.M.2
Krapcho, M.3
Neyman, N.4
Aminou, R.5
Altekruse, S.F.6
Kosary, C.L.7
Ruhl, J.8
Tatalovich, Z.9
Cho, H.10
Mariotto, A.11
Eisner, M.P.12
Lewis, D.R.13
Chen, H.S.14
Feuer, E.J.15
Cronin, K.A.16
-
2
-
-
84860389031
-
Cardiovascular disease competes with breast cancer as the leading cause of death for older females diagnosed with breast cancer: A retrospective cohort study
-
Patnaik JL, Byers T, Diguiseppi C, Dabelea D, Denberg TD. Cardiovascular disease competes with breast cancer as the leading cause of death for older females diagnosed with breast cancer: a retrospective cohort study. Breast Cancer Res. 2011;13:R64.
-
(2011)
Breast Cancer Res.
, vol.13
-
-
Patnaik, J.L.1
Byers, T.2
Diguiseppi, C.3
Dabelea, D.4
Denberg, T.D.5
-
3
-
-
33947730242
-
Long-term risk of cardiovascular disease in 10-year survivors of breast cancer
-
DOI 10.1093/jnci/djk064
-
Hooning MJ, Botma A, Aleman BM, Baaijens MH, Bartelink H, Klijn JG, Taylor CW, van Leeuwen FE. Long-term risk of cardiovascular disease in 10-year survivors of breast cancer. J Natl Cancer Inst. 2007;99:365-375. (Pubitemid 47073480)
-
(2007)
Journal of the National Cancer Institute
, vol.99
, Issue.5
, pp. 365-375
-
-
Hooning, M.J.1
Botma, A.2
Aleman, B.M.P.3
Baaijens, M.H.A.4
Bartelink, H.5
Klijn, J.G.M.6
Taylor, C.W.7
Van Leeuwen, F.E.8
-
4
-
-
0018716636
-
Risk factors for doxorubicin-induced congestive heart failure
-
Von Hoff DD, Layard MW, Basa P, Davis HL Jr, Von Hoff AL, Rozencweig M, Muggia FM. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med. 1979;91:710-717. (Pubitemid 10218041)
-
(1979)
Annals of Internal Medicine
, vol.91
, Issue.5
, pp. 710-717
-
-
Von Hoff, D.D.1
Layard, M.W.2
Basa, P.3
-
5
-
-
0038521374
-
Congestive heart failure in patients treated with doxorubicin: A retrospective analysis of three trials
-
DOI 10.1002/cncr.11407
-
Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer. 2003;97:2869-2879. (Pubitemid 36605157)
-
(2003)
Cancer
, vol.97
, Issue.11
, pp. 2869-2879
-
-
Swain, S.M.1
Whaley, F.S.2
Ewer, M.S.3
-
6
-
-
0035985273
-
Functional monitoring of anthracycline cardiotoxicity: A prospective, blinded, long-term observational study of outcome in 120 patients
-
DOI 10.1093/annonc/mdf132
-
Jensen BV, Skovsgaard T, Nielsen SL. Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients. Ann Oncol. 2002;13:699-709. (Pubitemid 34567375)
-
(2002)
Annals of Oncology
, vol.13
, Issue.5
, pp. 699-709
-
-
Jensen, B.V.1
Skovsgaard, T.2
Nielsen, S.L.3
-
7
-
-
0018102512
-
Anthracycline cardiomyopathy monitored by morphologic changes
-
Billingham ME, Mason JW, Bristow MR, Daniels JR. Anthracycline cardiomyopathy monitored by morphologic changes. Cancer Treat Rep. 1978;62:865-872. (Pubitemid 8377880)
-
(1978)
Cancer Treatment Reports
, vol.62
, Issue.6
, pp. 865-872
-
-
Billingham, M.E.1
Mason, J.W.2
Bristow, M.R.3
Daniels, J.R.4
-
8
-
-
0028348959
-
Assessment of anthracycline cardiomyopathy by endomyocardial biopsy
-
Mackay B, Ewer MS, Carrasco CH, Benjamin RS. Assessment of anthracycline cardiomyopathy by endomyocardial biopsy. Ultrastruct Pathol. 1994;18:203-211. (Pubitemid 24131629)
-
(1994)
Ultrastructural Pathology
, vol.18
, Issue.1-2
, pp. 203-211
-
-
Mackay, B.1
Ewer, M.S.2
Carrasco, C.H.3
Benjamin, R.S.4
-
9
-
-
79551610758
-
Cardiotoxicity of kinase inhibitors: The prediction and translation of preclinical models to clinical outcomes
-
Force T, Kolaja KL. Cardiotoxicity of kinase inhibitors: the prediction and translation of preclinical models to clinical outcomes. Nat Rev Drug Discov. 2011;10:111-126.
-
(2011)
Nat Rev Drug Discov.
, vol.10
, pp. 111-126
-
-
Force, T.1
Kolaja, K.L.2
-
10
-
-
84864042781
-
Trastuzumab containing regimens for early breast cancer
-
Moja L, Tagliabue L, Balduzzi S, Parmelli E, Pistotti V, Guarneri V, D'Amico R. Trastuzumab containing regimens for early breast cancer. Cochrane Database Syst Rev. 2012;4:CD006243.
-
(2012)
Cochrane Database Syst Rev.
, vol.4
-
-
Moja, L.1
Tagliabue, L.2
Balduzzi, S.3
Parmelli, E.4
Pistotti, V.5
Guarneri, V.6
D'Amico, R.7
-
11
-
-
19444378256
-
Type II chemotherapy-related cardiac dysfunction: Time to recognize a new entity
-
DOI 10.1200/JCO.2005.05.827
-
Ewer MS, Lippman SM. Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity. J Clin Oncol. 2005;23:2900-2902. (Pubitemid 46224107)
-
(2005)
Journal of Clinical Oncology
, vol.23
, Issue.13
, pp. 2900-2902
-
-
Ewer, M.S.1
Lippman, S.M.2
-
12
-
-
34548152541
-
Trastuzumab-related cardiotoxicity: Calling into question the concept of reversibility
-
DOI 10.1200/JCO.2007.11.0106
-
Telli ML, Hunt SA, Carlson RW, Guardino AE. Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility. J Clin Oncol. 2007;25:3525-3533. (Pubitemid 47310891)
-
(2007)
Journal of Clinical Oncology
, vol.25
, Issue.23
, pp. 3525-3533
-
-
Telli, M.L.1
Hunt, S.A.2
Carlson, R.W.3
Guardino, A.E.4
-
13
-
-
3142749673
-
ACC/AHA/ASNC guidelines for the clinical use of cardiac radionuclide imaging - Executive summary: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASNC Committee to revise the 1995 guidelines for the clinical use of cardiac radionuclide imaging)
-
DOI 10.1016/j.jacc.2003.08.011
-
Klocke FJ, Baird MG, Lorell BH, Bateman TM, Messer JV, Berman DS, O'Gara PT, Carabello BA, Russell RO Jr, Cerqueira MD, St John Sutton MG, De Maria AN, Udelson JE, Kennedy JW, Verani MS, Williams KA, Antman EM, Smith SC Jr, Alpert JS, Gregoratos G, Anderson JL, Hiratzka LF, Faxon DP, Hunt SA, Fuster V, Jacobs AK, Gibbons RJ, Russell RO. ACC/AHA/ASNC guidelines for the clinical use of cardiac radionuclide imaging-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASNC Committee to Revise the 1995 Guidelines for the Clinical Use of Cardiac Radionuclide Imaging). J Am Coll Cardiol. 2003;42:1318-1333. (Pubitemid 37188362)
-
(2003)
Journal of the American College of Cardiology
, vol.42
, Issue.7
, pp. 1318-1333
-
-
Klocke, F.J.1
Baird, M.G.2
Lorell, B.H.3
Bateman, T.M.4
Messer, J.V.5
Berman, D.S.6
O'Gara, P.T.7
Carabello, B.A.8
Russell Jr., R.O.9
Cerqueira, M.D.10
St. John Sutton, M.G.11
DeMaria, A.N.12
Udelson, J.E.13
Kennedy, J.W.14
Verani, M.S.15
Williams, K.A.16
Antman, E.M.17
Smith Jr., S.C.18
Alpert, J.S.19
Gregoratos, G.20
Anderson, J.L.21
Hiratzka, L.F.22
Faxon, D.P.23
Hunt, S.A.24
Fuster, V.25
Jacobs, A.K.26
Gibbons, R.J.27
Russell, R.O.28
more..
-
14
-
-
63849177462
-
2009 Focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the International Society for Heart and Lung Transplantation
-
Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, Jessup M, Konstam MA, Mancini DM, Michl K, Oates JA, Rahko PS, Silver MA, Stevenson LW, Yancy CW. 2009 Focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the International Society for Heart and Lung Transplantation. J Am Coll Cardiol. 2009;53:e1-e90.
-
(2009)
J Am Coll Cardiol.
, vol.53
-
-
Hunt, S.A.1
Abraham, W.T.2
Chin, M.H.3
Feldman, A.M.4
Francis, G.S.5
Ganiats, T.G.6
Jessup, M.7
Konstam, M.A.8
Mancini, D.M.9
Michl, K.10
Oates, J.A.11
Rahko, P.S.12
Silver, M.A.13
Stevenson, L.W.14
Yancy, C.W.15
-
15
-
-
65649119341
-
A woman's heart: The impact of adjuvant endocrine therapy on cardiovascular health
-
Ewer MS, Gluck S. A woman's heart: the impact of adjuvant endocrine therapy on cardiovascular health. Cancer. 2009;115:1813-1826.
-
(2009)
Cancer
, vol.115
, pp. 1813-1826
-
-
Ewer, M.S.1
Gluck, S.2
-
16
-
-
34848877728
-
Early breast cancer therapy and cardiovascular injury
-
DOI 10.1016/j.jacc.2007.06.037, PII S0735109707022401
-
Jones LW, Haykowsky MJ, Swartz JJ, Douglas PS, Mackey JR. Early breast cancer therapy and cardiovascular injury. J Am Coll Cardiol. 2007;50:1435-1441. (Pubitemid 47494586)
-
(2007)
Journal of the American College of Cardiology
, vol.50
, Issue.15
, pp. 1435-1441
-
-
Jones, L.W.1
Haykowsky, M.J.2
Swartz, J.J.3
Douglas, P.S.4
Mackey, J.R.5
-
19
-
-
0036498781
-
Cardiac dysfunction in the trastuzumab clinical trials experience
-
DOI 10.1200/JCO.20.5.1215
-
Seidman A, Hudis C, Pierri MK, Shak S, Paton V, Ashby M, Murphy M, Stewart SJ, Keefe D. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol. 2002;20:1215-1221. (Pubitemid 34177427)
-
(2002)
Journal of Clinical Oncology
, vol.20
, Issue.5
, pp. 1215-1221
-
-
Seidman, A.1
Hudis, C.2
Kathryn Pierri, M.3
Shak, S.4
Paton, V.5
Ashby, M.6
Murphy, M.7
Stewart, S.J.8
Keefe, D.9
-
20
-
-
29744442709
-
Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31
-
DOI 10.1200/JCO.2005.02.4091
-
Tan-Chiu E, Yothers G, Romond E, Geyer CE Jr, Ewer M, Keefe D, Shannon RP, Swain SM, Brown A, Fehrenbacher L, Vogel VG, Seay TE, Rastogi P, Mamounas EP, Wolmark N, Bryant J. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: Nsabp b-31. J Clin Oncol. 2005;23:7811-7819. (Pubitemid 46657378)
-
(2005)
Journal of Clinical Oncology
, vol.23
, Issue.31
, pp. 7811-7819
-
-
Tan-Chiu, E.1
Yothers, G.2
Romond, E.3
Geyer Jr., C.E.4
Ewer, M.5
Keefe, D.6
Shannon, R.P.7
Swain, S.M.8
Brown, A.9
Fehrenbacher, L.10
Vogel, V.G.11
Seay, T.E.12
Rastogi, P.13
Mamounas, E.P.14
Wolmark, N.15
Bryant, J.16
-
21
-
-
41649083764
-
Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 Adjuvant Breast Cancer Trial
-
Perez EA, Suman VJ, Davidson NE, Sledge GW, Kaufman PA, Hudis CA, Martino S, Gralow JR, Dakhil SR, Ingle JN, Winer EP, Gelmon KA, Gersh BJ, Jaffe AS, Rodeheffer RJ. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 Adjuvant Breast Cancer Trial. J Clin Oncol. 2008;26:1231-1238.
-
(2008)
J Clin Oncol.
, vol.26
, pp. 1231-1238
-
-
Perez, E.A.1
Suman, V.J.2
Davidson, N.E.3
Sledge, G.W.4
Kaufman, P.A.5
Hudis, C.A.6
Martino, S.7
Gralow, J.R.8
Dakhil, S.R.9
Ingle, J.N.10
Winer, E.P.11
Gelmon, K.A.12
Gersh, B.J.13
Jaffe, A.S.14
Rodeheffer, R.J.15
-
22
-
-
80053539103
-
Adjuvant trastuzumab in HER2-positive breast cancer
-
Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, Mackey J, Glaspy J, Chan A, Pawlicki M, Pinter T, Valero V, Liu MC, Sauter G, von Minckwitz G, Visco F, Bee V, Buyse M, Bendahmane B, Tabah-Fisch I, Lindsay MA, Riva A, Crown J. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011;365:1273-1283.
-
(2011)
N Engl J Med.
, vol.365
, pp. 1273-1283
-
-
Slamon, D.1
Eiermann, W.2
Robert, N.3
Pienkowski, T.4
Martin, M.5
Press, M.6
Mackey, J.7
Glaspy, J.8
Chan, A.9
Pawlicki, M.10
Pinter, T.11
Valero, V.12
Liu, M.C.13
Sauter, G.14
Von Minckwitz, G.15
Visco, F.16
Bee, V.17
Buyse, M.18
Bendahmane, B.19
Tabah-Fisch, I.20
Lindsay, M.A.21
Riva, A.22
Crown, J.23
more..
-
23
-
-
34347389664
-
Cardiotoxicity of trastuzumab in clinical practice
-
McArthur HL, Chia S. Cardiotoxicity of trastuzumab in clinical practice. N Engl J Med. 2007;357:94-95.
-
(2007)
N Engl J Med.
, vol.357
, pp. 94-95
-
-
McArthur, H.L.1
Chia, S.2
-
24
-
-
34548522479
-
American society of clinical oncology clinical evidence review on the ongoing care of adult cancer survivors: Cardiac and pulmonary late effects
-
DOI 10.1200/JCO.2007.10.9777
-
Carver JR, Shapiro CL, Ng A, Jacobs L, Schwartz C, Virgo KS, Hagerty KL, Somerfield MR, Vaughn DJ. American society of clinical oncology clinical evidence review on the ongoing care of adult cancer survivors: Cardiac and pulmonary late effects. J Clin Oncol. 2007;25:3991-4008. (Pubitemid 47477279)
-
(2007)
Journal of Clinical Oncology
, vol.25
, Issue.25
, pp. 3991-4008
-
-
Carver, J.R.1
Shapiro, C.L.2
Ng, A.3
Jacobs, L.4
Schwartz, C.5
Virgo, K.S.6
Hagerty, K.L.7
Somerfield, M.R.8
Vaughn, D.J.9
-
25
-
-
33644840267
-
Chemotherapy and cardiotoxicity in older breast cancer patients: A population-based study
-
DOI 10.1200/JCO.2005.02.5841
-
Doyle JJ, Neugut AI, Jacobson JS, Grann VR, Hershman DL. Chemotherapy and cardiotoxicity in older breast cancer patients: a population-based study. J Clin Oncol. 2005;23:8597-8605. (Pubitemid 46211501)
-
(2005)
Journal of Clinical Oncology
, vol.23
, Issue.34
, pp. 8597-8605
-
-
Doyle, J.J.1
Neugut, A.I.2
Jacobson, J.S.3
Grann, V.R.4
Hershman, D.L.5
-
26
-
-
34548481766
-
111Indium-trastuzumab visualises myocardial human epidermal growth factor receptor 2 expression shortly after anthracycline treatment but not during heart failure: A clue to uncover the mechanisms of trastuzumab-related cardiotoxicity
-
DOI 10.1016/j.ejca.2007.06.024, PII S0959804907005102
-
de Korte MA, de Vries EG, Lub-de Hooge MN, Jager PL, Gietema JA, van der Graaf WT, Sluiter WJ, van Veldhuisen DJ, Suter TM, Sleijfer DT, Perik PJ. 111Indium-trastuzumab visualises myocardial human epidermal growth factor receptor 2 expression shortly after anthracycline treatment but not during heart failure: a clue to uncover the mechanisms of trastuzumab-related cardiotoxicity. Eur J Cancer. 2007;43:2046-2051. (Pubitemid 47380360)
-
(2007)
European Journal of Cancer
, vol.43
, Issue.14
, pp. 2046-2051
-
-
De Korte, M.A.1
De Vries, E.G.E.2
Lub-De Hooge, M.N.3
Jager, P.L.4
Gietema, J.A.5
Van Der Graaf, W.T.A.6
Sluiter, W.J.7
Van Veldhuisen, D.J.8
Suter, T.M.9
Sleijfer, D.T.10
Perik, P.J.11
-
27
-
-
74049164266
-
The vulnerability of the heart as a pluricellular paracrine organ: Lessons from unexpected triggers of heart failure in targeted ErbB2 anticancer therapy
-
De Keulenaer GW, Doggen K, Lemmens K. The vulnerability of the heart as a pluricellular paracrine organ: lessons from unexpected triggers of heart failure in targeted ErbB2 anticancer therapy. Circ Res. 2010;106:35-46.
-
(2010)
Circ Res.
, vol.106
, pp. 35-46
-
-
De Keulenaer, G.W.1
Doggen, K.2
Lemmens, K.3
-
28
-
-
0036099675
-
ErbB2 is essential in the prevention of dilated cardiomyopathy
-
DOI 10.1038/nm0502-459
-
Crone SA, Zhao YY, Fan L, Gu Y, Minamisawa S, Liu Y, Peterson KL, Chen J, Kahn R, Condorelli G, Ross J Jr, Chien KR, Lee KF. ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat Med. 2002;8:459-465. (Pubitemid 34546747)
-
(2002)
Nature Medicine
, vol.8
, Issue.5
, pp. 459-465
-
-
Crone, S.A.1
Zhao, Y.-Y.2
Fan, L.3
Gu, Y.4
Minamisawa, S.5
Liu, Y.6
Peterson, K.L.7
Chen, J.8
Kahn, R.9
Condorelli, G.10
Ross Jr., J.11
Chien, K.R.12
Lee, K.-F.13
-
29
-
-
0037172982
-
Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy
-
DOI 10.1073/pnas.122249299
-
Ozcelik C, Erdmann B, Pilz B, Wettschureck N, Britsch S, Hubner N, Chien KR, Birchmeier C, Garratt AN. Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy. Proc Natl Acad Sci U S A. 2002;99:8880-8885. (Pubitemid 34693652)
-
(2002)
Proceedings of the National Academy of Sciences of the United States of America
, vol.99
, Issue.13
, pp. 8880-8885
-
-
Ozcelik, C.1
Erdmann, B.2
Pilz, B.3
Wettschureck, N.4
Britsch, S.5
Hubner, N.6
Chien, K.R.7
Birchmeier, C.8
Garratt, A.N.9
-
30
-
-
37649008623
-
Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: Safety analysis of BIG 1-98 trial
-
Mouridsen H, Keshaviah A, Coates AS, Rabaglio M, Castiglione-Gertsch M, Sun Z, Thurlimann B, Mauriac L, Forbes JF, Paridaens R, Gelber RD, Colleoni M, Smith I, Price KN, Goldhirsch A. Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: safety analysis of BIG 1-98 trial. J Clin Oncol. 2007;25:5715-5722.
-
(2007)
J Clin Oncol.
, vol.25
, pp. 5715-5722
-
-
Mouridsen, H.1
Keshaviah, A.2
Coates, A.S.3
Rabaglio, M.4
Castiglione-Gertsch, M.5
Sun, Z.6
Thurlimann, B.7
Mauriac, L.8
Forbes, J.F.9
Paridaens, R.10
Gelber, R.D.11
Colleoni, M.12
Smith, I.13
Price, K.N.14
Goldhirsch, A.15
-
31
-
-
38049095554
-
Do adjuvant aromatase inhibitors increase the cardiovascular risk in postmenopausal women with early breast cancer? Meta-analysis of randomized trials
-
Cuppone F, Bria E, Verma S, Pritchard KI, Gandhi S, Carlini P, Milella M, Nistico C, Terzoli E, Cognetti F, Giannarelli D. Do adjuvant aromatase inhibitors increase the cardiovascular risk in postmenopausal women with early breast cancer? Meta-analysis of randomized trials. Cancer. 2008;112:260-267.
-
(2008)
Cancer
, vol.112
, pp. 260-267
-
-
Cuppone, F.1
Bria, E.2
Verma, S.3
Pritchard, K.I.4
Gandhi, S.5
Carlini, P.6
Milella, M.7
Nistico, C.8
Terzoli, E.9
Cognetti, F.10
Giannarelli, D.11
-
32
-
-
14144252849
-
Changes in body fat and weight after a breast cancer diagnosis: Influence of demographic, prognostic, and lifestyle factors
-
DOI 10.1200/JCO.2005.04.036
-
Irwin ML, McTiernan A, Baumgartner RN, Baumgartner KB, Bernstein L, Gilliland FD, Ballard-Barbash R. Changes in body fat and weight after a breast cancer diagnosis: influence of demographic, prognostic, and lifestyle factors. J Clin Oncol. 2005;23:774-782. (Pubitemid 46224176)
-
(2005)
Journal of Clinical Oncology
, vol.23
, Issue.4
, pp. 774-782
-
-
Irwin, M.L.1
McTiernan, A.2
Baumgartner, R.N.3
Baumgartner, K.B.4
Bernstein, L.5
Gilliland, F.D.6
Ballard-Barbash, R.7
-
33
-
-
4744337709
-
Effects of an oncologist's recommendation to exercise on self-reported exercise behavior in newly diagnosed breast cancer survivors: A single-blind, randomized controlled trial
-
Jones LW, Courneya KS, Fairey AS, Mackey JR. Effects of an oncologist's recommendation to exercise on self-reported exercise behavior in newly diagnosed breast cancer survivors: a single-blind, randomized controlled trial. Ann Behav Med. 2004;28:105-113. (Pubitemid 39313356)
-
(2004)
Annals of Behavioral Medicine
, vol.28
, Issue.2
, pp. 105-113
-
-
Jones, L.W.1
Courneya, K.S.2
Fairey, A.S.3
Mackey, J.R.4
-
34
-
-
0037379173
-
Physical activity levels before and after a diagnosis of breast carcinoma: The health, eating, activity, and lifestyle (HEAL) study
-
DOI 10.1002/cncr.11227
-
Irwin ML, Crumley D, McTiernan A, Bernstein L, Baumgartner R, Gilliland FD, Kriska A, Ballard-Barbash R. Physical activity levels before and after a diagnosis of breast carcinoma: the Health, Eating, Activity, and Lifestyle (HEAL) study. Cancer. 2003;97:1746-1757. (Pubitemid 36350718)
-
(2003)
Cancer
, vol.97
, Issue.7
, pp. 1746-1757
-
-
Irwin, M.L.1
Crumley, D.2
McTiernan, A.3
Bernstein, L.4
Baumgartner, R.5
Gilliland, F.D.6
Kriska, A.7
Ballard-Barbash, R.8
-
35
-
-
84864028206
-
Cardiopulmonary function and age-related decline across the breast cancer survivorship continuum
-
Jones LW, Courneya KS, Mackey JR, Muss HB, Pituskin EN, Scott JM, Hornsby WE, Coan AD, Herndon JE 2nd, Douglas PS, Haykowsky M. Cardiopulmonary function and age-related decline across the breast cancer survivorship continuum. J Clin Oncol. 2012.
-
(2012)
J Clin Oncol.
-
-
Jones, L.W.1
Courneya, K.S.2
Mackey, J.R.3
Muss, H.B.4
Pituskin, E.N.5
Scott, J.M.6
Hornsby, W.E.7
Coan, A.D.8
Herndon II, J.E.9
Douglas, P.S.10
Haykowsky, M.11
-
36
-
-
0037031301
-
Prediction of long-term prognosis in 12 169 men referred for cardiac rehabilitation
-
DOI 10.1161/01.CIR.0000024413.15949.ED
-
Kavanagh T, Mertens DJ, Hamm LF, Beyene J, Kennedy J, Corey P, Shephard RJ. Prediction of long-term prognosis in 12 169 men referred for cardiac rehabilitation. Circulation. 2002;106:666-671. (Pubitemid 34851924)
-
(2002)
Circulation
, vol.106
, Issue.6
, pp. 666-671
-
-
Kavanagh, T.1
Mertens, D.J.2
Hamm, L.F.3
Beyene, J.4
Kennedy, J.5
Corey, P.6
Shephard, R.J.7
-
37
-
-
0346848737
-
Peak oxygen intake and cardiac mortality in women referred for cardiac rehabilitation
-
DOI 10.1016/j.jacc.2003.07.028
-
Kavanagh T, Mertens DJ, Hamm LF, Beyene J, Kennedy J, Corey P, Shephard RJ. Peak oxygen intake and cardiac mortality in women referred for cardiac rehabilitation. J Am Coll Cardiol. 2003;42:2139-2143. (Pubitemid 37549899)
-
(2003)
Journal of the American College of Cardiology
, vol.42
, Issue.12
, pp. 2139-2143
-
-
Kavanagh, T.1
Mertens, D.J.2
Hamm, L.F.3
Beyene, J.4
Kennedy, J.5
Corey, P.6
Shephard, R.J.7
-
38
-
-
2642566088
-
Anthracyclines: Molecular advances and pharmacologie developments in antitumor activity and cardiotoxicity
-
DOI 10.1124/pr.56.2.6
-
Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev. 2004;56:185-229. (Pubitemid 38720829)
-
(2004)
Pharmacological Reviews
, vol.56
, Issue.2
, pp. 185-229
-
-
Minotti, G.1
Menna, P.2
Salvatorelli, E.3
Cairo, G.4
Gianni, L.5
-
39
-
-
84860523994
-
Doxorubicin-induced cardiomyopathy: From molecular mechanisms to therapeutic strategies
-
Octavia Y, Tocchetti CG, Gabrielson KL, Janssens S, Crijns HJ, Moens AL. Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies. J Mol Cell Cardiol. 2012;52:1213-1225.
-
(2012)
J Mol Cell Cardiol.
, vol.52
, pp. 1213-1225
-
-
Octavia, Y.1
Tocchetti, C.G.2
Gabrielson, K.L.3
Janssens, S.4
Crijns, H.J.5
Moens, A.L.6
-
40
-
-
50949132320
-
Mechanisms of cardiac dysfunction associated with tyrosine kinase inhibitor cancer therapeutics
-
Chen MH, Kerkela R, Force T. Mechanisms of cardiac dysfunction associated with tyrosine kinase inhibitor cancer therapeutics. Circulation. 2008;118:84-95.
-
(2008)
Circulation
, vol.118
, pp. 84-95
-
-
Chen, M.H.1
Kerkela, R.2
Force, T.3
-
41
-
-
67649958842
-
Cardiovascular complications of cancer therapy: Incidence, pathogenesis, diagnosis, and management
-
Yeh ET, Bickford CL. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol. 2009;53:2231-2247.
-
(2009)
J Am Coll Cardiol.
, vol.53
, pp. 2231-2247
-
-
Yeh, E.T.1
Bickford, C.L.2
-
42
-
-
6044274062
-
Cardiovascular complications of cancer therapy: Diagnosis, pathogenesis, and management
-
Yeh ET, Tong AT, Lenihan DJ, Yusuf SW, Swafford J, Champion C, Durand JB, Gibbs H, Zafarmand AA, Ewer MS. Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. Circulation. 2004;109:3122-3131.
-
(2004)
Circulation
, vol.109
, pp. 3122-3131
-
-
Yeh, E.T.1
Tong, A.T.2
Lenihan, D.J.3
Yusuf, S.W.4
Swafford, J.5
Champion, C.6
Durand, J.B.7
Gibbs, H.8
Zafarmand, A.A.9
Ewer, M.S.10
-
43
-
-
80051494089
-
Modulation of anthracycline-induced cardiotoxicity by aerobic exercise in breast cancer: Current evidence and underlying mechanisms
-
Scott JM, Khakoo A, Mackey JR, Haykowsky MJ, Douglas PS, Jones LW. Modulation of anthracycline-induced cardiotoxicity by aerobic exercise in breast cancer: current evidence and underlying mechanisms. Circulation. 2011;124:642-650.
-
(2011)
Circulation
, vol.124
, pp. 642-650
-
-
Scott, J.M.1
Khakoo, A.2
Mackey, J.R.3
Haykowsky, M.J.4
Douglas, P.S.5
Jones, L.W.6
-
44
-
-
1542349778
-
Anthracyclines induce calpain-dependent titin proteolysis and necrosis in cardiomyocytes
-
DOI 10.1074/jbc.M308033200
-
Lim CC, Zuppinger C, Guo X, Kuster GM, Helmes M, Eppenberger HM, Suter TM, Liao R, Sawyer DB. Anthracyclines induce calpaindependent titin proteolysis and necrosis in cardiomyocytes. J Biol Chem. 2004;279:8290-8299. (Pubitemid 38294721)
-
(2004)
Journal of Biological Chemistry
, vol.279
, Issue.9
, pp. 8290-8299
-
-
Lim, C.C.1
Zuppinger, C.2
Guo, X.3
Kuster, G.M.4
Helmes, M.5
Eppenberger, H.M.6
Suter, T.M.7
Liao, R.8
Sawyer, D.B.9
-
45
-
-
77952618149
-
Role of heat shock factor-1 activation in the doxorubicininduced heart failure in mice
-
Vedam K, Nishijima Y, Druhan LJ, Khan M, Moldovan NI, Zweier JL, Ilangovan G. Role of heat shock factor-1 activation in the doxorubicininduced heart failure in mice. Am J Physiol Heart Circ Physiol. 2010;298:H1832-H1841.
-
(2010)
Am J Physiol Heart Circ Physiol.
, vol.298
-
-
Vedam, K.1
Nishijima, Y.2
Druhan, L.J.3
Khan, M.4
Moldovan, N.I.5
Zweier, J.L.6
Ilangovan, G.7
-
46
-
-
0037311110
-
Anthracycline-induced suppression of GATA-4 transcription factor: Implication in the regulation of cardiac myocyte apoptosis
-
DOI 10.1124/mol.63.2.368
-
Kim Y, Ma AG, Kitta K, Fitch SN, Ikeda T, Ihara Y, Simon AR, Evans T, Suzuki YJ. Anthracycline-induced suppression of GATA-4 transcription factor: Implication in the regulation of cardiac myocyte apoptosis. Mol Pharmacol. 2003;63:368-377. (Pubitemid 36158372)
-
(2003)
Molecular Pharmacology
, vol.63
, Issue.2
, pp. 368-377
-
-
Kim, Y.1
Ma, A.-G.2
Kitta, K.3
Fitch, S.N.4
Ikeda, T.5
Ihara, Y.6
Simon, A.R.7
Evans, T.8
Suzuki, Y.J.9
-
47
-
-
2342619408
-
Essential role of GATA-4 in cell survival and drug-induced cardiotoxicity
-
DOI 10.1073/pnas.0401833101
-
Aries A, Paradis P, Lefebvre C, Schwartz RJ, Nemer M. Essential role of GATA-4 in cell survival and drug-induced cardiotoxicity. Proc Natl Acad Sci U S A. 2004;101:6975-6980. (Pubitemid 38596428)
-
(2004)
Proceedings of the National Academy of Sciences of the United States of America
, vol.101
, Issue.18
, pp. 6975-6980
-
-
Aries, A.1
Paradis, P.2
Lefebvre, C.3
Schwartz, R.J.4
Nemer, M.5
-
48
-
-
76649144813
-
Juvenile exposure to anthracyclines impairs cardiac progenitor cell function and vascularization resulting in greater susceptibility to stress-induced myocardial injury in adult mice
-
Huang C, Zhang X, Ramil JM, Rikka S, Kim L, Lee Y, Gude NA, Thistlethwaite PA, Sussman MA, Gottlieb RA, Gustafsson AB. Juvenile exposure to anthracyclines impairs cardiac progenitor cell function and vascularization resulting in greater susceptibility to stress-induced myocardial injury in adult mice. Circulation. 2010;121:675-683.
-
(2010)
Circulation
, vol.121
, pp. 675-683
-
-
Huang, C.1
Zhang, X.2
Ramil, J.M.3
Rikka, S.4
Kim, L.5
Lee, Y.6
Gude, N.A.7
Thistlethwaite, P.A.8
Sussman, M.A.9
Gottlieb, R.A.10
Gustafsson, A.B.11
-
49
-
-
74949138296
-
Anthracycline cardiomyopathy is mediated by depletion of the cardiac stem cell pool and is rescued by restoration of progenitor cell function
-
De Angelis A, Piegari E, Cappetta D, Marino L, Filippelli A, Berrino L, Ferreira-Martins J, Zheng H, Hosoda T, Rota M, Urbanek K, Kajstura J, Leri A, Rossi F, Anversa P. Anthracycline cardiomyopathy is mediated by depletion of the cardiac stem cell pool and is rescued by restoration of progenitor cell function. Circulation. 2010;121:276-292.
-
(2010)
Circulation
, vol.121
, pp. 276-292
-
-
De Angelis, A.1
Piegari, E.2
Cappetta, D.3
Marino, L.4
Filippelli, A.5
Berrino, L.6
Ferreira-Martins, J.7
Zheng, H.8
Hosoda, T.9
Rota, M.10
Urbanek, K.11
Kajstura, J.12
Leri, A.13
Rossi, F.14
Anversa, P.15
-
50
-
-
34548336833
-
Molecular and cellular mechanisms of anthracycline cardiotoxicity
-
DOI 10.1007/s12012-007-0005-5
-
Chen B, Peng X, Pentassuglia L, Lim CC, Sawyer DB. Molecular and cellular mechanisms of anthracycline cardiotoxicity. Cardiovasc Toxicol. 2007;7:114-121. (Pubitemid 47339857)
-
(2007)
Cardiovascular Toxicology
, vol.7
, Issue.2
, pp. 114-121
-
-
Chen, B.1
Peng, X.2
Pentassuglia, L.3
Lim, C.C.4
Sawyer, D.B.5
-
51
-
-
0026006327
-
L-type cardiac calcium channels in doxorubicin cardiomyopathy in rats: Morphological, biochemical, and functional correlations
-
Keung EC, Toll L, Ellis M, Jensen RA. L-type cardiac calcium channels in doxorubicin cardiomyopathy in rats: morphological, biochemical, and functional correlations. J Clin Invest. 1991;87:2108-2113.
-
(1991)
J Clin Invest.
, vol.87
, pp. 2108-2113
-
-
Keung, E.C.1
Toll, L.2
Ellis, M.3
Jensen, R.A.4
-
52
-
-
0037023247
-
Doxorubicin directly binds to the cardiac-type ryanodine receptor
-
DOI 10.1016/S0024-3205(02)01524-2, PII S0024320502015242
-
Saeki K, Obi I, Ogiku N, Shigekawa M, Imagawa T, Matsumoto T. Doxorubicin directly binds to the cardiac-type ryanodine receptor. Life Sci. 2002;70:2377-2389. (Pubitemid 34261048)
-
(2002)
Life Sciences
, vol.70
, Issue.20
, pp. 2377-2389
-
-
Saeki, K.1
Obi, I.2
Ogiku, N.3
Shigekawa, M.4
Imagawa, T.5
Matsumoto, T.6
-
54
-
-
0037448784
-
Potent metalloporphyrin peroxynitrite decomposition catalyst protects against the development of doxorubicin-induced cardiac dysfunction
-
DOI 10.1161/01.CIR.0000048192.52098.DD
-
Pacher P, Liaudet L, Bai P, Mabley JG, Kaminski PM, Virag L, Deb A, Szabo E, Ungvari Z, Wolin MS, Groves JT, Szabo C. Potent metalloporphyrin peroxynitrite decomposition catalyst protects against the development of doxorubicin-induced cardiac dysfunction. Circulation. 2003;107:896-904. (Pubitemid 36241050)
-
(2003)
Circulation
, vol.107
, Issue.6
, pp. 896-904
-
-
Pacher, P.1
Liaudet, L.2
Bai, P.3
Mabley, J.G.4
Kaminski, P.M.5
Virag, L.6
Deb, A.7
Szabo, E.8
Ungvari, Z.9
Wolin, M.S.10
Groves, J.T.11
Szabo, C.12
-
55
-
-
66149110905
-
Role of superoxide, nitric oxide, and peroxynitrite in doxorubicin-induced cell death in vivo and in vitro
-
Mukhopadhyay P, Rajesh M, Batkai S, Kashiwaya Y, Hasko G, Liaudet L, Szabo C, Pacher P. Role of superoxide, nitric oxide, and peroxynitrite in doxorubicin-induced cell death in vivo and in vitro. Am J Physiol Heart Circ Physiol. 2009;296:H1466-H1483.
-
(2009)
Am J Physiol Heart Circ Physiol.
, vol.296
-
-
Mukhopadhyay, P.1
Rajesh, M.2
Batkai, S.3
Kashiwaya, Y.4
Hasko, G.5
Liaudet, L.6
Szabo, C.7
Pacher, P.8
-
56
-
-
21644455865
-
Acute toxicity of doxorubicin on isolated perfused heart: Response of kinases regulating energy supply
-
DOI 10.1152/ajpheart.01057.2004
-
Tokarska-Schlattner M, Zaugg M, da Silva R, Lucchinetti E, Schaub MC, Wallimann T, Schlattner U. Acute toxicity of doxorubicin on isolated perfused heart: response of kinases regulating energy supply. Am J Physiol Heart Circ Physiol. 2005;289:H37-H47. (Pubitemid 40934080)
-
(2005)
American Journal of Physiology - Heart and Circulatory Physiology
, vol.289
, Issue.1
-
-
Tokarska-Schlattner, M.1
Zaugg, M.2
Da Silva, R.3
Lucchinetti, E.4
Schaub, M.C.5
Wallimann, T.6
Schlattner, U.7
-
57
-
-
0034644539
-
Cell signaling by receptor tyrosine kinases
-
Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell. 2000;103:211-225.
-
(2000)
Cell
, vol.103
, pp. 211-225
-
-
Schlessinger, J.1
-
58
-
-
22044442973
-
Tyrosine kinases as targets for cancer therapy
-
DOI 10.1056/NEJMra044389
-
Krause DS, Van Etten RA. Tyrosine kinases as targets for cancer therapy. N Engl J Med. 2005;353:172-187. (Pubitemid 41058349)
-
(2005)
New England Journal of Medicine
, vol.353
, Issue.2
, pp. 172-187
-
-
Krause, D.S.1
Van Etten, R.A.2
-
59
-
-
34247480545
-
Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition
-
DOI 10.1038/nrc2106, PII NRC2106
-
Force T, Krause DS, Van Etten RA. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer. 2007;7:332-344. (Pubitemid 46652481)
-
(2007)
Nature Reviews Cancer
, vol.7
, Issue.5
, pp. 332-344
-
-
Force, T.1
Krause, D.S.2
Van Etten, R.A.3
-
60
-
-
74049125665
-
Molecular mechanisms of cardiovascular toxicity of targeted cancer therapeutics
-
Cheng H, Force T. Molecular mechanisms of cardiovascular toxicity of targeted cancer therapeutics. Circ Res. 2010;106:21-34.
-
(2010)
Circ Res.
, vol.106
, pp. 21-34
-
-
Cheng, H.1
Force, T.2
-
61
-
-
34548531901
-
Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial
-
DOI 10.1200/JCO.2006.09.1611
-
Suter TM, Procter M, van Veldhuisen DJ, Muscholl M, Bergh J, Carlomagno C, Perren T, Passalacqua R, Bighin C, Klijn JG, Ageev FT, Hitre E, Groetz J, Iwata H, Knap M, Gnant M, Muehlbauer S, Spence A, Gelber RD, Piccart-Gebhart MJ. Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol. 2007;25:3859-3865. (Pubitemid 47477261)
-
(2007)
Journal of Clinical Oncology
, vol.25
, Issue.25
, pp. 3859-3865
-
-
Suter, T.M.1
Procter, M.2
Van Veldhuisen, D.J.3
Muscholl, M.4
Bergh, J.5
Carlomagno, C.6
Perren, T.7
Passalacqua, R.8
Bighin, C.9
Klijn, J.G.M.10
Ageev, F.T.11
Hitre, E.12
Groetz, J.13
Iwata, H.14
Knap, M.15
Gnant, M.16
Muehlbauer, S.17
Spence, A.18
Gelber, R.D.19
Piccart-Gebhart, M.J.20
more..
-
62
-
-
33947594043
-
Efficacy and safety of single-agent pertuzumab (rhuMAb 2C4), a human epidermal growth factor receptor dimerization inhibitor, in castration-resistant prostate cancer after progression from taxane-based therapy
-
DOI 10.1200/JCO.2006.07.0649
-
Agus DB, Sweeney CJ, Morris MJ, Mendelson DS, McNeel DG, Ahmann FR, Wang J, Derynck MK, Ng K, Lyons B, Allison DE, Kattan MW, Scher HI. Efficacy and safety of single-agent pertuzumab (rhuMab 2C4), a human epidermal growth factor receptor dimerization inhibitor, in castration-resistant prostate cancer after progression from taxane-based therapy. J Clin Oncol. 2007;25:675-681. (Pubitemid 350002923)
-
(2007)
Journal of Clinical Oncology
, vol.25
, Issue.6
, pp. 675-681
-
-
Agus, D.B.1
Sweeney, C.J.2
Morris, M.J.3
Mendelson, D.S.4
McNeel, D.G.5
Ahmann, F.R.6
Wang, J.7
Derynck, M.K.8
Ng, K.9
Lyons, B.10
Allison, D.E.11
Kattan, M.W.12
Scher, H.I.13
-
63
-
-
44949253343
-
Cardiac safety of lapatinib: Pooled analysis of 3689 patients enrolled in clinical trials
-
DOI 10.4065/83.6.679
-
Perez EA, Koehler M, Byrne J, Preston AJ, Rappold E, Ewer MS. Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials. Mayo Clin Proc. 2008;83:679-686. (Pubitemid 351810568)
-
(2008)
Mayo Clinic Proceedings
, vol.83
, Issue.6
, pp. 679-686
-
-
Perez, E.A.1
Koehler, M.2
Byrne, J.3
Preston, A.J.4
Rappold, E.5
Ewer, M.S.6
-
64
-
-
68249087127
-
Neuregulin-1 beta is associated with disease severity and adverse outcomes in chronic heart failure
-
Ky B, Kimmel SE, Safa RN, Putt ME, Sweitzer NK, Fang JC, Sawyer DB, Cappola TP. Neuregulin-1 beta is associated with disease severity and adverse outcomes in chronic heart failure. Circulation. 2009;120:310-317.
-
(2009)
Circulation
, vol.120
, pp. 310-317
-
-
Ky, B.1
Kimmel, S.E.2
Safa, R.N.3
Putt, M.E.4
Sweitzer, N.K.5
Fang, J.C.6
Sawyer, D.B.7
Cappola, T.P.8
-
65
-
-
59049093631
-
Blockade of the erbb2 receptor induces cardiomyocyte death through mitochondrial and reactive oxygen species-dependent pathways
-
Gordon LI, Burke MA, Singh AT, Prachand S, Lieberman ED, Sun L, Naik TJ, Prasad SV, Ardehali H. Blockade of the erbb2 receptor induces cardiomyocyte death through mitochondrial and reactive oxygen species-dependent pathways. J Biol Chem. 2009;284:2080-2087.
-
(2009)
J Biol Chem.
, vol.284
, pp. 2080-2087
-
-
Gordon, L.I.1
Burke, M.A.2
Singh, A.T.3
Prachand, S.4
Lieberman, E.D.5
Sun, L.6
Naik, T.J.7
Prasad, S.V.8
Ardehali, H.9
-
66
-
-
78149338262
-
Neuregulin-1beta1 rapidly modulates nitric oxide synthesis and calcium handling in rat cardiomyocytes
-
Brero A, Ramella R, Fitou A, Dati C, Alloatti G, Gallo MP, Levi R. Neuregulin-1beta1 rapidly modulates nitric oxide synthesis and calcium handling in rat cardiomyocytes. Cardiovasc Res. 2010;88:443-452.
-
(2010)
Cardiovasc Res.
, vol.88
, pp. 443-452
-
-
Brero, A.1
Ramella, R.2
Fitou, A.3
Dati, C.4
Alloatti, G.5
Gallo, M.P.6
Levi, R.7
-
67
-
-
62649116580
-
The role of neuregulin-1beta/ErbB signaling in the heart
-
Pentassuglia L, Sawyer DB. The role of neuregulin-1beta/ErbB signaling in the heart. Exp Cell Res. 2009;315:627-637.
-
(2009)
Exp Cell Res.
, vol.315
, pp. 627-637
-
-
Pentassuglia, L.1
Sawyer, D.B.2
-
68
-
-
33746048823
-
Neuregulin activates erbB2-dependent src/FAK signaling and cytoskeletal remodeling in isolated adult rat cardiac myocytes
-
DOI 10.1016/j.yjmcc.2006.04.007, PII S0022282806005347
-
Kuramochi Y, Guo X, Sawyer DB. Neuregulin activates erbB2-dependent src/FAK signaling and cytoskeletal remodeling in isolated adult rat cardiac myocytes. J Mol Cell Cardiol. 2006;41:228-235. (Pubitemid 44080212)
-
(2006)
Journal of Molecular and Cellular Cardiology
, vol.41
, Issue.2
, pp. 228-235
-
-
Kuramochi, Y.1
Guo, X.2
Sawyer, D.B.3
-
69
-
-
33748929841
-
Neuregulin-1/erbB-activation improves cardiac function and survival in models of ischemic, dilated, and viral cardiomyopathy
-
DOI 10.1016/j.jacc.2006.05.057, PII S0735109706017980
-
Liu X, Gu X, Li Z, Li X, Li H, Chang J, Chen P, Jin J, Xi B, Chen D, Lai D, Graham RM, Zhou M. Neuregulin-1/ErbB-activation improves cardiac function and survival in models of ischemic, dilated, and viral cardiomyopathy. J Am Coll Cardiol. 2006;48:1438-1447. (Pubitemid 44436803)
-
(2006)
Journal of the American College of Cardiology
, vol.48
, Issue.7
, pp. 1438-1447
-
-
Liu, X.1
Gu, X.2
Li, Z.3
Li, X.4
Li, H.5
Chang, J.6
Chen, P.7
Jin, J.8
Xi, B.9
Chen, D.10
Lai, D.11
Graham, R.M.12
Zhou, M.13
-
70
-
-
79955052182
-
Activation of the neuregulin/ErbB system during physiological ventricular remodeling in pregnancy
-
Lemmens K, Doggen K, De Keulenaer GW. Activation of the neuregulin/ErbB system during physiological ventricular remodeling in pregnancy. Am J Physiol Heart Circ Physiol. 2011;300:H931-H942.
-
(2011)
Am J Physiol Heart Circ Physiol.
, vol.300
-
-
Lemmens, K.1
Doggen, K.2
De Keulenaer, G.W.3
-
71
-
-
34547537264
-
Activation of AMP-activated protein kinase by human EGF receptor 2/EGF receptor tyrosine kinase inhibitor protects cardiac cells
-
DOI 10.1073/pnas.0701286104
-
Spector NL, Yarden Y, Smith B, Lyass L, Trusk P, Pry K, Hill JE, Xia W, Seger R, Bacus SS. Activation of AMP-activated protein kinase by human EGF receptor 2/EGF receptor tyrosine kinase inhibitor protects cardiac cells. Proc Natl Acad Sci U S A. 2007;104:10607-10612. (Pubitemid 47185712)
-
(2007)
Proceedings of the National Academy of Sciences of the United States of America
, vol.104
, Issue.25
, pp. 10607-10612
-
-
Spector, N.L.1
Yarden, Y.2
Smith, B.3
Lyass, L.4
Trusk, P.5
Pry, K.6
Hill, J.E.7
Xia, W.8
Seger, R.9
Bacus, S.S.10
-
72
-
-
0029096747
-
Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomised trial: The Scottish Cancer Trials Breast Group
-
McDonald CC, Alexander FE, Whyte BW, Forrest AP, Stewart HJ. Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomised trial: the Scottish Cancer Trials Breast Group. BMJ. 1995;311:977-980.
-
(1995)
BMJ
, vol.311
, pp. 977-980
-
-
McDonald, C.C.1
Alexander, F.E.2
Whyte, B.W.3
Forrest, A.P.4
Stewart, H.J.5
-
73
-
-
0025931791
-
Effects of tamoxifen on cardiovascular risk factors in postmenopausal women
-
Love RR, Wiebe DA, Newcomb PA, Cameron L, Leventhal H, Jordan VC, Feyzi J, De Mets DL. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women. Ann Intern Med. 1991;115:860-864.
-
(1991)
Ann Intern Med.
, vol.115
, pp. 860-864
-
-
Love, R.R.1
Wiebe, D.A.2
Newcomb, P.A.3
Cameron, L.4
Leventhal, H.5
Jordan, V.C.6
Feyzi, J.7
De Mets, D.L.8
-
74
-
-
0026764412
-
Long term effects of tamoxifen on blood lipid values in breast cancer
-
Dewar JA, Horobin JM, Preece PE, Tavendale R, Tunstall-Pedoe H, Wood RA. Long term effects of tamoxifen on blood lipid values in breast cancer. BMJ. 1992;305:225-226.
-
(1992)
BMJ
, vol.305
, pp. 225-226
-
-
Dewar, J.A.1
Horobin, J.M.2
Preece, P.E.3
Tavendale, R.4
Tunstall-Pedoe, H.5
Wood, R.A.6
-
75
-
-
0344233260
-
Meta-analysis of vascular and neoplastic events associated with tamoxifen
-
DOI 10.1046/j.1525-1497.2003.20724.x
-
Braithwaite RS, Chlebowski RT, Lau J, George S, Hess R, Col NF. Meta-analysis of vascular and neoplastic events associated with tamoxifen. J Gen Intern Med. 2003;18:937-947. (Pubitemid 37510624)
-
(2003)
Journal of General Internal Medicine
, vol.18
, Issue.11
, pp. 937-947
-
-
Braithwaite, R.S.1
Chlebowski, R.T.2
Lau, J.3
George, S.4
Hess, R.5
Col, N.F.6
-
76
-
-
34247247163
-
Decreased risk of stroke among 10-year survivors of breast cancer
-
DOI 10.1200/JCO.2006.06.5516
-
Hooning MJ, Dorresteijn LD, Aleman BM, Kappelle AC, Klijn JG, Boogerd W, van Leeuwen FE. Decreased risk of stroke among 10-year survivors of breast cancer. J Clin Oncol. 2006;24:5388-5394. (Pubitemid 46623170)
-
(2006)
Journal of Clinical Oncology
, vol.24
, Issue.34
, pp. 5388-5394
-
-
Hooning, M.J.1
Dorresteijn, L.D.A.2
Aleman, B.M.P.3
Kappelle, A.C.4
Klijn, J.G.M.5
Boogerd, W.6
Van Leeuwen, F.E.7
-
77
-
-
11444251764
-
Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer
-
Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, Hoctin-Boes G, Houghton J, Locker GY, Tobias JS. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet. 2005;365:60-62.
-
(2005)
Lancet
, vol.365
, pp. 60-62
-
-
Howell, A.1
Cuzick, J.2
Baum, M.3
Buzdar, A.4
Dowsett, M.5
Forbes, J.F.6
Hoctin-Boes, G.7
Houghton, J.8
Locker, G.Y.9
Tobias, J.S.10
-
78
-
-
29544433211
-
A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer
-
DOI 10.1056/NEJMoa052258
-
Thurlimann B, Keshaviah A, Coates AS, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Rabaglio M, Smith I, Wardley A, Price KN, Goldhirsch A. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med. 2005;353:2747-2757. (Pubitemid 43016814)
-
(2005)
New England Journal of Medicine
, vol.353
, Issue.26
, pp. 2747-2757
-
-
Thurlimann, B.1
Keshaviah, A.2
Coates, A.S.3
Mouridsen, H.4
Mauriac, L.5
Forbes, J.F.6
Paridaens, R.7
Castiglione-Gertsch, M.8
Gelber, R.D.9
Rabaglio, M.10
Smith, I.11
Wardly, A.12
Price, K.N.13
Goldhirsch, A.14
-
79
-
-
33846545851
-
Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): A randomised controlled trial
-
Coombes RC, Kilburn LS, Snowdon CF, Paridaens R, Coleman RE, Jones SE, Jassem J, Van de Velde CJ, Delozier T, Alvarez I, Del Mastro L, Ortmann O, Diedrich K, Coates AS, Bajetta E, Holmberg SB, Dodwell D, Mickiewicz E, Andersen J, Lonning PE, Cocconi G, Forbes J, Castiglione M, Stuart N, Stewart A, Fallowfield LJ, Bertelli G, Hall E, Bogle RG, Carpentieri M, Colajori E, Subar M, Ireland E, Bliss JM. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet. 2007;369:559-570.
-
(2007)
Lancet
, vol.369
, pp. 559-570
-
-
Coombes, R.C.1
Kilburn, L.S.2
Snowdon, C.F.3
Paridaens, R.4
Coleman, R.E.5
Jones, S.E.6
Jassem, J.7
Van De Velde, C.J.8
Delozier, T.9
Alvarez, I.10
Del Mastro, L.11
Ortmann, O.12
Diedrich, K.13
Coates, A.S.14
Bajetta, E.15
Holmberg, S.B.16
Dodwell, D.17
Mickiewicz, E.18
Andersen, J.19
Lonning, P.E.20
Cocconi, G.21
Forbes, J.22
Castiglione, M.23
Stuart, N.24
Stewart, A.25
Fallowfield, L.J.26
Bertelli, G.27
Hall, E.28
Bogle, R.G.29
Carpentieri, M.30
Colajori, E.31
Subar, M.32
Ireland, E.33
Bliss, J.M.34
more..
-
80
-
-
24744450378
-
Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: Updated findings from NCIC CTG MA.17
-
DOI 10.1093/jnci/dji250
-
Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Cameron DA, Palmer MJ, Pater JL. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst. 2005;97:1262-1271. (Pubitemid 41535367)
-
(2005)
Journal of the National Cancer Institute
, vol.97
, Issue.17
, pp. 1262-1271
-
-
Goss, P.E.1
Ingle, J.N.2
Martino, S.3
Robert, N.J.4
Muss, H.B.5
Piccart, M.J.6
Castiglione, M.7
Tu, D.8
Shepherd, L.E.9
Pritchard, K.I.10
Livingston, R.B.11
Davidson, N.E.12
Norton, L.13
Perez, E.A.14
Abrams, J.S.15
Cameron, D.A.16
Palmer, M.J.17
Pater, J.L.18
-
81
-
-
41849088117
-
Detection and monitoring of cardiotoxicity: What does modern cardiology offer?
-
Jurcut R, Wildiers H, Ganame J, D'Hooge J, Paridaens R, Voigt JU. Detection and monitoring of cardiotoxicity: what does modern cardiology offer? Support Care Cancer. 2008;16:437-445.
-
(2008)
Support Care Cancer.
, vol.16
, pp. 437-445
-
-
Jurcut, R.1
Wildiers, H.2
Ganame, J.3
D'Hooge, J.4
Paridaens, R.5
Voigt, J.U.6
-
82
-
-
63449100553
-
Cardiovascular toxicity caused by cancer treatment: Strategies for early detection
-
Altena R, Perik PJ, van Veldhuisen DJ, de Vries EG, Gietema JA. Cardiovascular toxicity caused by cancer treatment: strategies for early detection. Lancet Oncol. 2009;10:391-399.
-
(2009)
Lancet Oncol.
, vol.10
, pp. 391-399
-
-
Altena, R.1
Perik, P.J.2
Van Veldhuisen, D.J.3
De Vries, E.G.4
Gietema, J.A.5
-
83
-
-
0021356510
-
A comparison of cardiac biopsy grades and ejection fraction estimations in patients receiving adriamycin
-
Ewer MS, Ali MK, Mackay B, Wallace S, Valdivieso M, Legha SS, Benjamin RS, Haynie TP. A comparison of cardiac biopsy grades and ejection fraction estimations in patients receiving adriamycin. J Clin Oncol. 1984;2:112-117. (Pubitemid 14152453)
-
(1984)
Journal of Clinical Oncology
, vol.2
, Issue.2
, pp. 112-117
-
-
Ewer, M.S.1
Ali, M.K.2
Mackay, B.3
-
84
-
-
84858684483
-
Pretreatment and routine echocardiogram monitoring during chemotherapy for anthracycline-induced cardiotoxicity rarely identifies significant cardiac dysfunction or alters treatment decisions: A 5-year review at a single pediatric oncology center
-
Watts RG, George M, Johnson WH Jr. Pretreatment and routine echocardiogram monitoring during chemotherapy for anthracycline-induced cardiotoxicity rarely identifies significant cardiac dysfunction or alters treatment decisions: a 5-year review at a single pediatric oncology center. Cancer. 2012;118:1919-1924.
-
(2012)
Cancer
, vol.118
, pp. 1919-1924
-
-
Watts, R.G.1
George, M.2
Johnson Jr., W.H.3
-
85
-
-
41649103274
-
Left ventricular ejection fraction and cardiotoxicity: Is our ear really to the ground?
-
Ewer MS, Lenihan DJ. Left ventricular ejection fraction and cardiotoxicity: is our ear really to the ground? J Clin Oncol. 2008;26:1201-1203.
-
(2008)
J Clin Oncol.
, vol.26
, pp. 1201-1203
-
-
Ewer, M.S.1
Lenihan, D.J.2
-
87
-
-
51649092308
-
Cardiac management during adjuvant trastuzumab therapy: Recommendations of the Canadian Trastuzumab Working Group
-
Mackey JR, Clemons M, Cote MA, Delgado D, Dent S, Paterson A, Provencher L, Sawyer MB, Verma S. Cardiac management during adjuvant trastuzumab therapy: recommendations of the Canadian Trastuzumab Working Group. Curr Oncol. 2008;15:24-35.
-
(2008)
Curr Oncol.
, vol.15
, pp. 24-35
-
-
Mackey, J.R.1
Clemons, M.2
Cote, M.A.3
Delgado, D.4
Dent, S.5
Paterson, A.6
Provencher, L.7
Sawyer, M.B.8
Verma, S.9
-
88
-
-
84870586873
-
-
package insert, San Francisco, CA: Genentech, Inc
-
Trastuzumab (Herceptin) [package insert]. San Francisco, CA: Genentech, Inc.
-
Trastuzumab (Herceptin)
-
-
-
89
-
-
79955515055
-
Is cardiotoxicity being adequately assessed in current trials of cytotoxic and targeted agents in breast cancer?
-
Verma S, Ewer MS. Is cardiotoxicity being adequately assessed in current trials of cytotoxic and targeted agents in breast cancer? Ann Oncol. 2011;22:1011-1018.
-
(2011)
Ann Oncol.
, vol.22
, pp. 1011-1018
-
-
Verma, S.1
Ewer, M.S.2
-
90
-
-
0033855860
-
Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy
-
Cardinale D, Sandri MT, Martinoni A, Tricca A, Civelli M, Lamantia G, Cinieri S, Martinelli G, Cipolla CM, Fiorentini C. Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy. J Am Coll Cardiol. 2000;36:517-522.
-
(2000)
J Am Coll Cardiol.
, vol.36
, pp. 517-522
-
-
Cardinale, D.1
Sandri, M.T.2
Martinoni, A.3
Tricca, A.4
Civelli, M.5
Lamantia, G.6
Cinieri, S.7
Martinelli, G.8
Cipolla, C.M.9
Fiorentini, C.10
-
91
-
-
0035985276
-
Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapy
-
DOI 10.1093/annonc/mdf170
-
Cardinale D, Sandri MT, Martinoni A, Borghini E, Civelli M, Lamantia G, Cinieri S, Martinelli G, Fiorentini C, Cipolla CM. Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapy. Ann Oncol. 2002;13:710-715. (Pubitemid 34567376)
-
(2002)
Annals of Oncology
, vol.13
, Issue.5
, pp. 710-715
-
-
Cardinale, D.1
Sandri, M.T.2
Martinoni, A.3
Borghini, E.4
Civelli, M.5
Lamantia, G.6
Cinieri, S.7
Martinelli, G.8
Fiorentini, C.9
Cipolla, C.M.10
-
92
-
-
0037307057
-
Minor increases in plasma troponin I predict decreased left ventricular ejection fraction after high-dose chemotherapy
-
DOI 10.1373/49.2.248
-
Sandri MT, Cardinale D, Zorzino L, Passerini R, Lentati P, Martinoni A, Martinelli G, Cipolla CM. Minor increases in plasma troponin I predict decreased left ventricular ejection fraction after high-dose chemotherapy. Clin Chem. 2003;49:248-252. (Pubitemid 36143446)
-
(2003)
Clinical Chemistry
, vol.49
, Issue.2
, pp. 248-252
-
-
Sandri, M.T.1
Cardinale, D.2
Zorzino, L.3
Passerini, R.4
Lentati, P.5
Martinoni, A.6
Martinelli, G.7
Cipolla, C.M.8
-
93
-
-
0037505494
-
Prolonged monitoring of troponin T for the detection of anthracycline cardiotoxicity in adults with hematological malignancies
-
Auner HW, Tinchon C, Linkesch W, Tiran A, Quehenberger F, Link H, Sill H. Prolonged monitoring of troponin T for the detection of anthracycline cardiotoxicity in adults with hematological malignancies. Ann Hematol. 2003;82:218-222. (Pubitemid 36701012)
-
(2003)
Annals of Hematology
, vol.82
, Issue.4
, pp. 218-222
-
-
Auner, H.W.1
Tinchon, C.2
Linkesch, W.3
Tiran, A.4
Quehenberger, F.5
Link, H.6
Sill, H.7
-
94
-
-
77957567061
-
Trastuzumab-induced cardiotoxicity: Clinical and prognostic implications of troponin I evaluation
-
Cardinale D, Colombo A, Torrisi R, Sandri MT, Civelli M, Salvatici M, Lamantia G, Colombo N, Cortinovis S, Dessanai MA, Nole F, Veglia F, Cipolla CM. Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. J Clin Oncol. 2010;28:3910-3916.
-
(2010)
J Clin Oncol.
, vol.28
, pp. 3910-3916
-
-
Cardinale, D.1
Colombo, A.2
Torrisi, R.3
Sandri, M.T.4
Civelli, M.5
Salvatici, M.6
Lamantia, G.7
Colombo, N.8
Cortinovis, S.9
Dessanai, M.A.10
Nole, F.11
Veglia, F.12
Cipolla, C.M.13
-
95
-
-
20044376854
-
CTnT can be a useful marker for early detection of anthracycline cardiotoxicity
-
DOI 10.1093/annonc/mdi152
-
Kilickap S, Barista I, Akgul E, Aytemir K, Aksoyek S, Aksoy S, Celik I, Kes S, Tekuzman G. CTNT can be a useful marker for early detection of anthracycline cardiotoxicity. Ann Oncol. 2005;16:798-804. (Pubitemid 40767103)
-
(2005)
Annals of Oncology
, vol.16
, Issue.5
, pp. 798-804
-
-
Kilickap, S.1
Barista, I.2
Akgul, E.3
Aytemir, K.4
Aksoyek, S.5
Aksoy, S.6
Celik, I.7
Kes, S.8
Tekuzman, G.9
-
96
-
-
79954593490
-
Early detection and prediction of cardiotoxicity in chemotherapy-treated patients
-
Sawaya H, Sebag IA, Plana JC, Januzzi JL, Ky B, Cohen V, Gosavi S, Carver JR, Wiegers SE, Martin RP, Picard MH, Gerszten RE, Halpern EF, Passeri J, Kuter I, Scherrer-Crosbie M. Early detection and prediction of cardiotoxicity in chemotherapy-treated patients. Am J Cardiol. 2011;107:1375-1380.
-
(2011)
Am J Cardiol.
, vol.107
, pp. 1375-1380
-
-
Sawaya, H.1
Sebag, I.A.2
Plana, J.C.3
Januzzi, J.L.4
Ky, B.5
Cohen, V.6
Gosavi, S.7
Carver, J.R.8
Wiegers, S.E.9
Martin, R.P.10
Picard, M.H.11
Gerszten, R.E.12
Halpern, E.F.13
Passeri, J.14
Kuter, I.15
Scherrer-Crosbie, M.16
-
97
-
-
79955989608
-
Troponin I and C-reactive protein are commonly detected in patients with breast cancer treated with dose-dense chemotherapy incorporating trastuzumab and lapatinib
-
Morris PG, Chen C, Steingart R, Fleisher M, Lin N, Moy B, Come S, Sugarman S, Abbruzzi A, Lehman R, Patil S, Dickler M, McArthur HL, Winer E, Norton L, Hudis CA, Dang CT. Troponin I and C-reactive protein are commonly detected in patients with breast cancer treated with dose-dense chemotherapy incorporating trastuzumab and lapatinib. Clin Cancer Res. 2011;17:3490-3499.
-
(2011)
Clin Cancer Res.
, vol.17
, pp. 3490-3499
-
-
Morris, P.G.1
Chen, C.2
Steingart, R.3
Fleisher, M.4
Lin, N.5
Moy, B.6
Come, S.7
Sugarman, S.8
Abbruzzi, A.9
Lehman, R.10
Patil, S.11
Dickler, M.12
McArthur, H.L.13
Winer, E.14
Norton, L.15
Hudis, C.A.16
Dang, C.T.17
-
98
-
-
23044510968
-
N-terminal pro-B-type natriuretic peptide after high-dose chemotherapy: A marker predictive of cardiac dysfunction?
-
DOI 10.1373/clinchem.2005.050153
-
Sandri MT, Salvatici M, Cardinale D, Zorzino L, Passerini R, Lentati P, Leon M, Civelli M, Martinelli G, Cipolla CM. N-terminal pro-B-type natriuretic peptide after high-dose chemotherapy: a marker predictive of cardiac dysfunction? Clin Chem. 2005;51:1405-1410. (Pubitemid 41060872)
-
(2005)
Clinical Chemistry
, vol.51
, Issue.8
, pp. 1405-1410
-
-
Sandri, M.T.1
Salvatici, M.2
Cardinale, D.3
Zorzino, L.4
Passerini, R.5
Lentati, P.6
Leon, M.7
Civelli, M.8
Martinelli, G.9
Cipolla, C.M.10
-
99
-
-
44249089575
-
Usefulness of myocardial performance index and biochemical markers for early detection of anthracycline-induced cardiotoxicity in adults
-
DOI 10.1007/s00392-007-0633-6
-
Dodos F, Halbsguth T, Erdmann E, Hoppe UC. Usefulness of myocardial performance index and biochemical markers for early detection of anthracycline-induced cardiotoxicity in adults. Clin Res Cardiol. 2008;97:318-326. (Pubitemid 351725058)
-
(2008)
Clinical Research in Cardiology
, vol.97
, Issue.5
, pp. 318-326
-
-
Dodos, F.1
Halbsguth, T.2
Erdmann, E.3
Hoppe, U.C.4
-
100
-
-
11844290705
-
Natriuretic peptides in the monitoring of anthracycline induced reduction in left ventricular ejection fraction
-
DOI 10.1016/j.ejheart.2004.03.009, PII S1388984204001059
-
Daugaard G, Lassen U, Bie P, Pedersen EB, Jensen KT, Abildgaard U, Hesse B, Kjaer A. Natriuretic peptides in the monitoring of anthracycline induced reduction in left ventricular ejection fraction. Eur J Heart Fail. 2005;7:87-93. (Pubitemid 40092497)
-
(2005)
European Journal of Heart Failure
, vol.7
, Issue.1
, pp. 87-93
-
-
Daugaard, G.1
Lassen, U.2
Bie, P.3
Pedersen, E.B.4
Jensen, K.T.5
Abildgaard, U.6
Hesse, B.7
Kjaer, A.8
-
101
-
-
17644388763
-
Drug-induced cardiotoxicity studied by longitudinal B-type natriuretic peptide assays and radionuclide ventriculography
-
Pichon MF, Cvitkovic F, Hacene K, Delaunay J, Lokiec F, Collignon MA, Pecking AP. Drug-induced cardiotoxicity studied by longitudinal B-type natriuretic peptide assays and radionuclide ventriculography. In Vivo. 2005;19:567-576. (Pubitemid 40568136)
-
(2005)
Vivo
, vol.19
, Issue.3
, pp. 567-576
-
-
Pichon, M.-F.1
Cvitkovic, F.2
Hacene, K.3
Delaunay, J.4
Lokiec, F.5
Colllignon, M.-A.6
Pecking, A.-P.7
-
102
-
-
77955907895
-
Role of biomarkers in chemotherapy-induced cardiotoxicity
-
Cardinale D, Sandri MT. Role of biomarkers in chemotherapy-induced cardiotoxicity. Prog Cardiovasc Dis. 2010;53:121-129.
-
(2010)
Prog Cardiovasc Dis.
, vol.53
, pp. 121-129
-
-
Cardinale, D.1
Sandri, M.T.2
-
103
-
-
23844534811
-
Reporting recommendations for tumor marker prognostic studies (REMARK)
-
DOI 10.1093/jnci/dji237
-
McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK). J Natl Cancer Inst. 2005;97:1180-1184. (Pubitemid 41258223)
-
(2005)
Journal of the National Cancer Institute
, vol.97
, Issue.16
, pp. 1180-1184
-
-
McShane, L.M.1
Altman, D.G.2
Sauerbrei, W.3
Taube, S.E.4
Gion, M.5
Clark, G.M.6
Costa, J.7
Di Leo, A.8
Mayer, R.J.9
-
104
-
-
44749086940
-
Assessment of left ventricular systolic function using echocardiography in patients with preserved ejection fraction and elevated diastolic pressures
-
Dokainish H, Sengupta R, Pillai M, Bobek J, Lakkis N. Assessment of left ventricular systolic function using echocardiography in patients with preserved ejection fraction and elevated diastolic pressures. Am J Cardiol. 2008;101:1766-1771.
-
(2008)
Am J Cardiol.
, vol.101
, pp. 1766-1771
-
-
Dokainish, H.1
Sengupta, R.2
Pillai, M.3
Bobek, J.4
Lakkis, N.5
-
105
-
-
0036073312
-
Myocardial function defined by strain rate and strain during alterations in inotropic states and heart rate
-
Weidemann F, Jamal F, Sutherland GR, Claus P, Kowalski M, Hatle L, De Scheerder I, Bijnens B, Rademakers FE. Myocardial function defined by strain rate and strain during alterations in inotropic states and heart rate. Am J Physiol Heart Circ Physiol. 2002;283:H792-H799. (Pubitemid 34790876)
-
(2002)
American Journal of Physiology - Heart and Circulatory Physiology
, vol.283
, Issue.2
-
-
Weidemann, F.1
Jamal, F.2
Sutherland, G.R.3
Claus, P.4
Kowalski, M.5
Hatle, L.6
De Scheerder, I.7
Bijnens, B.8
Rademakers, F.E.9
-
106
-
-
33748061258
-
Tissue Doppler imaging predicts left ventricular dysfunction and mortality in a murine model of cardiac injury
-
DOI 10.1093/eurheartj/ehl013
-
Neilan TG, Jassal DS, Perez-Sanz TM, Raher MJ, Pradhan AD, Buys ES, Ichinose F, Bayne DB, Halpern EF, Weyman AE, Derumeaux G, Bloch KD, Picard MH, Scherrer-Crosbie M. Tissue Doppler imaging predicts left ventricular dysfunction and mortality in a murine model of cardiac injury. Eur Heart J. 2006;27:1868-1875. (Pubitemid 44297395)
-
(2006)
European Heart Journal
, vol.27
, Issue.15
, pp. 1868-1875
-
-
Neilan, T.G.1
Jassal, D.S.2
Perez-Sanz, T.M.3
Raher, M.J.4
Pradhan, A.D.5
Buys, E.S.6
Ichinose, F.7
Bayne, D.B.8
Halpern, E.F.9
Weyman, A.E.10
Derumeaux, G.11
Bloch, K.D.12
Picard, M.H.13
Scherrer-Crosbie, M.14
-
107
-
-
36549085519
-
Myocardial Dysfunction Late After Low-Dose Anthracycline Treatment in Asymptomatic Pediatric Patients
-
DOI 10.1016/j.echo.2007.04.007, PII S0894731707002866
-
Ganame J, Claus P, Uyttebroeck A, Renard M, D'Hooge J, Bijnens B, Sutherland GR, Eyskens B, Mertens L. Myocardial dysfunction late after low-dose anthracycline treatment in asymptomatic pediatric patients. J Am Soc Echocardiogr. 2007;20:1351-1358. (Pubitemid 350181316)
-
(2007)
Journal of the American Society of Echocardiography
, vol.20
, Issue.12
, pp. 1351-1358
-
-
Ganame, J.1
Claus, P.2
Uyttebroeck, A.3
Renard, M.4
D'hooge, J.5
Bijnens, B.6
Sutherland, G.R.7
Eyskens, B.8
Mertens, L.9
-
108
-
-
56549101641
-
Strain rate imaging detects early cardiac effects of pegylated liposomal doxorubicin as adjuvant therapy in elderly patients with breast cancer
-
Jurcut R, Wildiers H, Ganame J, D'Hooge J, De Backer J, Denys H, Paridaens R, Rademakers F, Voigt JU. Strain rate imaging detects early cardiac effects of pegylated liposomal doxorubicin as adjuvant therapy in elderly patients with breast cancer. J Am Soc Echocardiogr. 2008;21:1283-1289.
-
(2008)
J Am Soc Echocardiogr.
, vol.21
, pp. 1283-1289
-
-
Jurcut, R.1
Wildiers, H.2
Ganame, J.3
D'Hooge, J.4
De Backer, J.5
Denys, H.6
Paridaens, R.7
Rademakers, F.8
Voigt, J.U.9
-
109
-
-
67650351539
-
Use of myocardial deformation imaging to detect preclinical myocardial dysfunction before conventional measures in patients undergoing breast cancer treatment with trastuzumab
-
Hare JL, Brown JK, Leano R, Jenkins C, Woodward N, Marwick TH. Use of myocardial deformation imaging to detect preclinical myocardial dysfunction before conventional measures in patients undergoing breast cancer treatment with trastuzumab. Am Heart J. 2009;158:294-301.
-
(2009)
Am Heart J
, vol.158
, pp. 294-301
-
-
Hare, J.L.1
Brown, J.K.2
Leano, R.3
Jenkins, C.4
Woodward, N.5
Marwick, T.H.6
-
110
-
-
35548936125
-
Early epirubicin-induced myocardial dysfunction revealed by serial tissue Doppler echocardiography: Correlation with inflammatory and oxidative stress markers
-
DOI 10.1634/theoncologist.12-9-1124
-
Mercuro G, Cadeddu C, Piras A, Dessi M, Madeddu C, Deidda M, Serpe R, Massa E, Mantovani G. Early epirubicin-induced myocardial dysfunction revealed by serial tissue Doppler echocardiography: correlation with inflammatory and oxidative stress markers. Oncologist. 2007;12:1124-1133. (Pubitemid 350007024)
-
(2007)
Oncologist
, vol.12
, Issue.9
, pp. 1124-1133
-
-
Mercuro, G.1
Cadeddu, C.2
Piras, A.3
Dessi, M.4
Madeddu, C.5
Deidda, M.6
Serpe, R.7
Massa, E.8
Mantovani, G.9
-
111
-
-
77955294878
-
Role of three-dimensional echocardiography in breast cancer: Comparison with two-dimensional echocardiography, multiple-gated acquisition scans, and cardiac magnetic resonance imaging
-
Walker J, Bhullar N, Fallah-Rad N, Lytwyn M, Golian M, Fang T, Summers AR, Singal PK, Barac I, Kirkpatrick ID, Jassal DS. Role of three-dimensional echocardiography in breast cancer: comparison with two-dimensional echocardiography, multiple-gated acquisition scans, and cardiac magnetic resonance imaging. J Clin Oncol. 2010;28:3429-3436.
-
(2010)
J Clin Oncol.
, vol.28
, pp. 3429-3436
-
-
Walker, J.1
Bhullar, N.2
Fallah-Rad, N.3
Lytwyn, M.4
Golian, M.5
Fang, T.6
Summers, A.R.7
Singal, P.K.8
Barac, I.9
Kirkpatrick, I.D.10
Jassal, D.S.11
-
112
-
-
84865092873
-
Screening adult survivors of childhood cancer for cardiomyopathy: Comparison of echocardiography and cardiac magnetic resonance imaging
-
Armstrong GT, Plana JC, Zhang N, Srivastava D, Green DM, Ness KK, Daniel Donovan F, Metzger ML, Arevalo A, Durand JB, Joshi V, Hudson MM, Robison LL, Flamm SD. Screening adult survivors of childhood cancer for cardiomyopathy: comparison of echocardiography and cardiac magnetic resonance imaging. J Clin Oncol. 2012;30:2876-2884.
-
(2012)
J Clin Oncol.
, vol.30
, pp. 2876-2884
-
-
Armstrong, G.T.1
Plana, J.C.2
Zhang, N.3
Srivastava, D.4
Green, D.M.5
Ness, K.K.6
Daniel Donovan, F.7
Metzger, M.L.8
Arevalo, A.9
Durand, J.B.10
Joshi, V.11
Hudson, M.M.12
Robison, L.L.13
Flamm, S.D.14
-
113
-
-
0035370698
-
Subclinical cardiotoxic effects of anthracyclines as assessed by magnetic resonance imaging - A pilot study
-
DOI 10.1067/mhj.2001.115436
-
Wassmuth R, Lentzsch S, Erdbruegger U, Schulz-Menger J, Doerken B, Dietz R, Friedrich MG. Subclinical cardiotoxic effects of anthracyclines as assessed by magnetic resonance imaging: a pilot study. Am Heart J. 2001;141:1007-1013. (Pubitemid 32477014)
-
(2001)
American Heart Journal
, vol.141
, Issue.6
, pp. 1007-1013
-
-
Wassmuth, R.1
Lentzsch, S.2
Erdbruegger, U.3
Schulz-Menger, J.4
Doerken, B.5
Dietz, R.6
Friedrich, M.G.7
-
114
-
-
77957367762
-
Novel approach to early detection of doxorubicin cardiotoxicity by gadolinium-enhanced cardiovascular magnetic resonance imaging in an experimental model
-
Lightfoot JC, D'Agostino RB Jr, Hamilton CA, Jordan J, Torti FM, Kock ND, Workman S, Hundley WG. Novel approach to early detection of doxorubicin cardiotoxicity by gadolinium-enhanced cardiovascular magnetic resonance imaging in an experimental model. Circ Cardiovasc Imaging. 2010;3:550-558.
-
(2010)
Circ Cardiovasc Imaging
, vol.3
, pp. 550-558
-
-
Lightfoot, J.C.1
D'Agostino Jr., R.B.2
Hamilton, C.A.3
Jordan, J.4
Torti, F.M.5
Kock, N.D.6
Workman, S.7
Hundley, W.G.8
-
115
-
-
73949084826
-
Aortic stiffness increases upon receipt of anthracycline chemotherapy
-
Chaosuwannakit N, D'Agostino R Jr, Hamilton CA, Lane KS, Ntim WO, Lawrence J, Melin SA, Ellis LR, Torti FM, Little WC, Hundley WG. Aortic stiffness increases upon receipt of anthracycline chemotherapy. J Clin Oncol. 2010;28:166-172.
-
(2010)
J Clin Oncol.
, vol.28
, pp. 166-172
-
-
Chaosuwannakit, N.1
Agostino Jr., D.R.2
Hamilton, C.A.3
Lane, K.S.4
Ntim, W.O.5
Lawrence, J.6
Melin, S.A.7
Ellis, L.R.8
Torti, F.M.9
Little, W.C.10
Hundley, W.G.11
-
116
-
-
79954587093
-
Scintigraphic techniques for early detection of cancer treatment-induced cardiotoxicity
-
de Geus-Oei LF, Mavinkurve-Groothuis AM, Bellersen L, Gotthardt M, Oyen WJ, Kapusta L, van Laarhoven HW. Scintigraphic techniques for early detection of cancer treatment-induced cardiotoxicity. J Nucl Med. 2011;52:560-571.
-
(2011)
J Nucl Med.
, vol.52
, pp. 560-571
-
-
De Geus-Oei, L.F.1
Mavinkurve-Groothuis, A.M.2
Bellersen, L.3
Gotthardt, M.4
Oyen, W.J.5
Kapusta, L.6
Van Laarhoven, H.W.7
-
117
-
-
66149119027
-
Exercise intolerance in cancer and the role of exercise therapy to reverse dysfunction
-
Jones LW, Eves ND, Haykowsky M, Freedland SJ, Mackey JR. Exercise intolerance in cancer and the role of exercise therapy to reverse dysfunction. Lancet Oncol. 2009;10:598-605.
-
(2009)
Lancet Oncol.
, vol.10
, pp. 598-605
-
-
Jones, L.W.1
Eves, N.D.2
Haykowsky, M.3
Freedland, S.J.4
Mackey, J.R.5
-
118
-
-
77958578806
-
Cardioprotective effect of metoprolol and enalapril in doxorubicin-treated lymphoma patients: A prospective, parallel-group, randomized, controlled study with 36-month follow-up
-
Georgakopoulos P, Roussou P, Matsakas E, Karavidas A, Anagnostopoulos N, Marinakis T, Galanopoulos A, Georgiakodis F, Zimeras S, Kyriakidis M, Ahimastos A. Cardioprotective effect of metoprolol and enalapril in doxorubicin-treated lymphoma patients: a prospective, parallel-group, randomized, controlled study with 36-month follow-up. Am J Hematol. 2010;85:894-896.
-
(2010)
Am J Hematol.
, vol.85
, pp. 894-896
-
-
Georgakopoulos, P.1
Roussou, P.2
Matsakas, E.3
Karavidas, A.4
Anagnostopoulos, N.5
Marinakis, T.6
Galanopoulos, A.7
Georgiakodis, F.8
Zimeras, S.9
Kyriakidis, M.10
Ahimastos, A.11
-
119
-
-
28044442932
-
Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone
-
DOI 10.1002/cncr.21478
-
Nakamae H, Tsumura K, Terada Y, Nakane T, Nakamae M, Ohta K, Yamane T, Hino M. Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone. Cancer. 2005;104:2492-2498. (Pubitemid 41691573)
-
(2005)
Cancer
, vol.104
, Issue.11
, pp. 2492-2498
-
-
Nakamae, H.1
Tsumura, K.2
Terada, Y.3
Nakane, T.4
Nakamae, M.5
Ohta, K.6
Yamane, T.7
Hino, M.8
-
120
-
-
77956363811
-
Protective effects of the angiotensin II receptor blocker telmisartan on epirubicin-induced inflammation, oxidative stress, and early ventricular impairment
-
e481-e487
-
Cadeddu C, Piras A, Mantovani G, Deidda M, Dessi M, Madeddu C, Massa E, Mercuro G. Protective effects of the angiotensin II receptor blocker telmisartan on epirubicin-induced inflammation, oxidative stress, and early ventricular impairment. Am Heart J. 2010;160:487 e481-e487.
-
(2010)
Am Heart J
, vol.160
, pp. 487
-
-
Cadeddu, C.1
Piras, A.2
Mantovani, G.3
Deidda, M.4
Dessi, M.5
Madeddu, C.6
Massa, E.7
Mercuro, G.8
-
121
-
-
33845206791
-
Protective effects of carvedilol against anthracycline-induced cardiomyopathy
-
DOI 10.1016/j.jacc.2006.07.052, PII S0735109706022005
-
Kalay N, Basar E, Ozdogru I, Er O, Cetinkaya Y, Dogan A, Inanc T, Oguzhan A, Eryol NK, Topsakal R, Ergin A. Protective effects of carvedilol against anthracycline-induced cardiomyopathy. J Am Coll Cardiol. 2006;48:2258-2262. (Pubitemid 44855419)
-
(2006)
Journal of the American College of Cardiology
, vol.48
, Issue.11
, pp. 2258-2262
-
-
Kalay, N.1
Basar, E.2
Ozdogru, I.3
Er, O.4
Cetinkaya, Y.5
Dogan, A.6
Inanc, T.7
Oguzhan, A.8
Eryol, N.K.9
Topsakal, R.10
Ergin, A.11
-
122
-
-
84860416553
-
Efficiency of atorvastatin in the protection of anthracyclineinduced cardiomyopathy
-
Acar Z, Kale A, Turgut M, Demircan S, Durna K, Demir S, Meric M, Agac MT. Efficiency of atorvastatin in the protection of anthracyclineinduced cardiomyopathy. J Am Coll Cardiol. 2011;58:988-989.
-
(2011)
J Am Coll Cardiol.
, vol.58
, pp. 988-989
-
-
Acar, Z.1
Kale, A.2
Turgut, M.3
Demircan, S.4
Durna, K.5
Demir, S.6
Meric, M.7
Agac, M.T.8
-
123
-
-
33845402341
-
Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition
-
DOI 10.1161/CIRCULATIONAHA.106.635144, PII 0000301720061205000010
-
Cardinale D, Colombo A, Sandri MT, Lamantia G, Colombo N, Civelli M, Martinelli G, Veglia F, Fiorentini C, Cipolla CM. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation. 2006;114:2474-2481. (Pubitemid 44901520)
-
(2006)
Circulation
, vol.114
, Issue.23
, pp. 2474-2481
-
-
Cardinale, D.1
Colombo, A.2
Sandri, M.T.3
Lamantia, G.4
Colombo, N.5
Civelli, M.6
Martinelli, G.7
Veglia, F.8
Fiorentini, C.9
Cipolla, C.M.10
-
124
-
-
68049139569
-
Adjuvant trastuzumab induces ventricular remodeling despite aerobic exercise training
-
Haykowsky MJ, Mackey JR, Thompson RB, Jones LW, Paterson DI. Adjuvant trastuzumab induces ventricular remodeling despite aerobic exercise training. Clin Cancer Res. 2009;15:4963-4967.
-
(2009)
Clin Cancer Res.
, vol.15
, pp. 4963-4967
-
-
Haykowsky, M.J.1
Mackey, J.R.2
Thompson, R.B.3
Jones, L.W.4
Paterson, D.I.5
-
125
-
-
80051531200
-
Effects of aerobic training to improve cardiovascular function and prevent cardiac remodeling after cytotoxic therapy in early breast cancer
-
April 2-6, Orlando, FL. Philadelphia, PA: AACR No. 502
-
Jones L, Dolinsky V, Haykowsky M, Patterson D, Douglas P, Allen J, Scott J, Rogan K, Khouri M, Hornsby W, Young M, Peppercorn J, Kimmick G, Dyck J. Effects of aerobic training to improve cardiovascular function and prevent cardiac remodeling after cytotoxic therapy in early breast cancer. Paper presented at: 102nd Annual Meeting of the American Association for Cancer Research; April 2-6, 2011; Orlando, FL. Philadelphia, PA: AACR No. (502).
-
(2011)
102nd Annual Meeting of the American Association for Cancer Research
-
-
Jones, L.1
Dolinsky, V.2
Haykowsky, M.3
Patterson, D.4
Douglas, P.5
Allen, J.6
Scott, J.7
Rogan, K.8
Khouri, M.9
Hornsby, W.10
Young, M.11
Peppercorn, J.12
Kimmick, G.13
Dyck, J.14
-
126
-
-
79960691560
-
Rationale and design of the Multidisciplinary Approach to Novel Therapies in Cardiology Oncology Research Trial (MANTICORE 101-Breast): A randomized, placebo-controlled trial to determine if conventional heart failure pharmacotherapy can prevent trastuzumab-mediated left ventricular remodeling among patients with HER2+ early breast cancer using cardiac MRI
-
Pituskin E, Haykowsky M, Mackey JR, Thompson RB, Ezekowitz J, Koshman S, Oudit G, Chow K, Pagano JJ, Paterson I. Rationale and design of the Multidisciplinary Approach to Novel Therapies in Cardiology Oncology Research Trial (MANTICORE 101-Breast): a randomized, placebo-controlled trial to determine if conventional heart failure pharmacotherapy can prevent trastuzumab-mediated left ventricular remodeling among patients with HER2+ early breast cancer using cardiac MRI. BMC Cancer. 2011;11:318.
-
(2011)
BMC Cancer
, vol.11
, pp. 318
-
-
Pituskin, E.1
Haykowsky, M.2
Mackey, J.R.3
Thompson, R.B.4
Ezekowitz, J.5
Koshman, S.6
Oudit, G.7
Chow, K.8
Pagano, J.J.9
Paterson, I.10
-
127
-
-
79961004271
-
Prevention of chemotherapy-induced left ventricular dysfunction with enalapril and carvedilol: Rationale and design of the OVERCOME trial
-
Bosch X, Esteve J, Sitges M, de Caralt TM, Domenech A, Ortiz JT, Monzo M, Morales-Ruiz M, Perea RJ, Rovira M. Prevention of chemotherapy-induced left ventricular dysfunction with enalapril and carvedilol: rationale and design of the OVERCOME trial. J Card Fail. 2011;17:643-648.
-
(2011)
J Card Fail
, vol.17
, pp. 643-648
-
-
Bosch, X.1
Esteve, J.2
Sitges, M.3
De Caralt, T.M.4
Domenech, A.5
Ortiz, J.T.6
Monzo, M.7
Morales-Ruiz, M.8
Perea, R.J.9
Rovira, M.10
-
128
-
-
0023693833
-
Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer
-
Speyer JL, Green MD, Kramer E, Rey M, Sanger J, Ward C, Dubin N, Ferrans V, Stecy P, Zeleniuch-Jacquotte A, Wernz J, Feit F, Slater W, Blum R, Muggia F. Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer. N Engl J Med. 1988;319:745-752.
-
(1988)
N Engl J Med.
, vol.319
, pp. 745-752
-
-
Speyer, J.L.1
Green, M.D.2
Kramer, E.3
Rey, M.4
Sanger, J.5
Ward, C.6
Dubin, N.7
Ferrans, V.8
Stecy, P.9
Zeleniuch-Jacquotte, A.10
Wernz, J.11
Feit, F.12
Slater, W.13
Blum, R.14
Muggia, F.15
-
129
-
-
58149335531
-
American Society of Clinical Oncology 2008 clinical practice guideline update: Use of chemotherapy and radiation therapy protectants
-
Hensley ML, Hagerty KL, Kewalramani T, Green DM, Meropol NJ, Wasserman TH, Cohen GI, Emami B, Gradishar WJ, Mitchell RB, Thigpen JT, Trotti A 3rd, von Hoff D, Schuchter LM. American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants. J Clin Oncol. 2009;27:127-145.
-
(2009)
J Clin Oncol.
, vol.27
, pp. 127-145
-
-
Hensley, M.L.1
Hagerty, K.L.2
Kewalramani, T.3
Green, D.M.4
Meropol, N.J.5
Wasserman, T.H.6
Cohen, G.I.7
Emami, B.8
Gradishar, W.J.9
Mitchell, R.B.10
Thigpen, J.T.11
Trotti III, A.12
Von Hoff, D.13
Schuchter, L.M.14
-
130
-
-
0031654596
-
Adult multicenter trials using dexrazoxane to protect against cardiac toxicity
-
Swain SM. Adult multicenter trials using dexrazoxane to protect against cardiac toxicity. Semin Oncol. 1998;25:43-47. (Pubitemid 28460383)
-
(1998)
Seminars in Oncology
, vol.25
, Issue.4 SUPPL. 10
, pp. 43-47
-
-
Swain, S.M.1
-
132
-
-
0037716744
-
Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic dysfunction: A follow-up study
-
DOI 10.1016/S0140-6736(03)13501-5
-
Jong P, Yusuf S, Rousseau MF, Ahn SA, Bangdiwala SI. Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic dysfunction: a follow-up study. Lancet. 2003;361:1843-1848. (Pubitemid 36645177)
-
(2003)
Lancet
, vol.361
, Issue.9372
, pp. 1843-1848
-
-
Jong, P.1
Yusuf, S.2
Rousseau, M.F.3
Ahn, S.A.4
Bangdiwala, S.I.5
-
133
-
-
0035810547
-
Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: The CAPRICORN randomised trial
-
DOI 10.1016/S0140-6736(00)04560-8
-
Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet. 2001;357:1385-1390. (Pubitemid 32455364)
-
(2001)
Lancet
, vol.357
, Issue.9266
, pp. 1385-1390
-
-
Dargie, H.J.1
-
134
-
-
73549087024
-
Anthracycline-induced cardiomyopathy: Clinical relevance and response to pharmacologic therapy
-
Cardinale D, Colombo A, Lamantia G, Colombo N, Civelli M, De Giacomi G, Rubino M, Veglia F, Fiorentini C, Cipolla CM. Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol. 2010;55:213-220.
-
(2010)
J Am Coll Cardiol.
, vol.55
, pp. 213-220
-
-
Cardinale, D.1
Colombo, A.2
Lamantia, G.3
Colombo, N.4
Civelli, M.5
De Giacomi, G.6
Rubino, M.7
Veglia, F.8
Fiorentini, C.9
Cipolla, C.M.10
-
135
-
-
20344401818
-
Mechanisms and models in heart failure: The biomechanical model and beyond
-
DOI 10.1161/CIRCULATIONAHA.104.500546
-
Mann DL, Bristow MR. Mechanisms and models in heart failure: the biomechanical model and beyond. Circulation. 2005;111:2837-2849. (Pubitemid 40791557)
-
(2005)
Circulation
, vol.111
, Issue.21
, pp. 2837-2849
-
-
Mann, D.L.1
Bristow, M.R.2
-
136
-
-
0035203981
-
Potential protective role of angiotensin-converting enzyme inhibitors captopril and enalapril against adriamycin-induced acute cardiac and hepatic toxicity in rats
-
DOI 10.1002/jat.782
-
Abd El-Aziz MA, Othman AI, Amer M, El-Missiry MA. Potential protective role of angiotensin-converting enzyme inhibitors captopril and enalapril against adriamycin-induced acute cardiac and hepatic toxicity in rats. J Appl Toxicol. 2001;21:469-473. (Pubitemid 33130747)
-
(2001)
Journal of Applied Toxicology
, vol.21
, Issue.6
, pp. 469-473
-
-
Abd El-Aziz, M.A.1
Othman, A.I.2
Amer, M.3
El-Missiry, M.A.4
-
137
-
-
0036944046
-
Carvedilol protects against doxorubicin-induced mitochondrial cardiomyopathy
-
DOI 10.1006/taap.2002.9532
-
Santos DL, Moreno AJ, Leino RL, Froberg MK, Wallace KB. Carvedilol protects against doxorubicin-induced mitochondrial cardiomyopathy. Toxicol Appl Pharmacol. 2002;185:218-227. (Pubitemid 36062795)
-
(2002)
Toxicology and Applied Pharmacology
, vol.185
, Issue.3
, pp. 218-227
-
-
Santos, D.L.1
Moreno, A.J.M.2
Leino, R.L.3
Froberg, M.K.4
Wallace, K.B.5
-
138
-
-
4544228968
-
Carvedilol prevents doxorubicin-induced free radical release and apoptosis in cardiomyocytes in vitro
-
DOI 10.1016/j.yjmcc.2004.05.024, PII S0022282804001658
-
Spallarossa P, Garibaldi S, Altieri P, Fabbi P, Manca V, Nasti S, Rossettin P, Ghigliotti G, Ballestrero A, Patrone F, Barsotti A, Brunelli C. Carvedilol prevents doxorubicin-induced free radical release and apoptosis in cardiomyocytes in vitro. J Mol Cell Cardiol. 2004;37:837-846. (Pubitemid 39222076)
-
(2004)
Journal of Molecular and Cellular Cardiology
, vol.37
, Issue.4
, pp. 837-846
-
-
Spallarossa, P.1
Garibaldi, S.2
Altieri, P.3
Fabbi, P.4
Manca, V.5
Nasti, S.6
Rossettin, P.7
Ghigliotti, G.8
Ballestrero, A.9
Patrone, F.10
Barsotti, A.11
Brunelli, C.12
-
139
-
-
58349097915
-
Pretreatment with statin attenuates the cardiotoxicity of doxorubicin in mice
-
Riad A, Bien S, Westermann D, Becher PM, Loya K, Landmesser U, Kroemer HK, Schultheiss HP, Tschope C. Pretreatment with statin attenuates the cardiotoxicity of doxorubicin in mice. Cancer Res. 2009;69:695-699.
-
(2009)
Cancer Res.
, vol.69
, pp. 695-699
-
-
Riad, A.1
Bien, S.2
Westermann, D.3
Becher, P.M.4
Loya, K.5
Landmesser, U.6
Kroemer, H.K.7
Schultheiss, H.P.8
Tschope, C.9
-
140
-
-
80052328841
-
Inhibition of Rac1 signaling by lovastatin protects against anthracyclineinduced cardiac toxicity
-
Huelsenbeck J, Henninger C, Schad A, Lackner KJ, Kaina B, Fritz G. Inhibition of Rac1 signaling by lovastatin protects against anthracyclineinduced cardiac toxicity. Cell Death Dis. 2011;2:e190.
-
(2011)
Cell Death Dis.
, vol.2
-
-
Huelsenbeck, J.1
Henninger, C.2
Schad, A.3
Lackner, K.J.4
Kaina, B.5
Fritz, G.6
-
141
-
-
0037420124
-
Amlodipine inhibits doxorubicin-induced apoptosis in neonatal rat cardiac myocytes
-
DOI 10.1016/S0735-1097(02)02935-2
-
Yamanaka S, Tatsumi T, Shiraishi J, Mano A, Keira N, Matoba S, Asayama J, Fushiki S, Fliss H, Nakagawa M. Amlodipine inhibits doxorubicin-induced apoptosis in neonatal rat cardiac myocytes. J Am Coll Cardiol. 2003;41:870-878. (Pubitemid 36308399)
-
(2003)
Journal of the American College of Cardiology
, vol.41
, Issue.5
, pp. 870-878
-
-
Yamanaka, S.1
Tatsumi, T.2
Shiraishi, J.3
Mano, A.4
Keira, N.5
Matoba, S.6
Asayama, J.7
Fushiki, S.8
Fliss, H.9
Nakagawa, M.10
-
142
-
-
17144405644
-
Phosphodiesterase-5 inhibition with sildenafil attenuates cardiomyocyte apoptosis and left ventricular dysfunction in a chronic model of doxorubicin cardiotoxicity
-
DOI 10.1161/01.CIR.0000160359.49478.C2
-
Fisher PW, Salloum F, Das A, Hyder H, Kukreja RC. Phosphodiesterase-5 inhibition with sildenafil attenuates cardiomyocyte apoptosis and left ventricular dysfunction in a chronic model of doxorubicin cardiotoxicity. Circulation. 2005;111:1601-1610. (Pubitemid 40525159)
-
(2005)
Circulation
, vol.111
, Issue.13
, pp. 1601-1610
-
-
Fisher, P.W.1
Salloum, F.2
Das, A.3
Hyder, H.4
Kukreja, R.C.5
-
143
-
-
35948941885
-
The endothelin receptor blocker bosentan inhibits doxorubicin-induced cardiomyopathy
-
DOI 10.1158/0008-5472.CAN-07-1344
-
Bien S, Riad A, Ritter CA, Gratz M, Olshausen F, Westermann D, Grube M, Krieg T, Ciecholewski S, Felix SB, Staudt A, Schultheiss HP, Ewert R, Volker U, Tschope C, Kroemer HK. The endothelin receptor blocker bosentan inhibits doxorubicin-induced cardiomyopathy. Cancer Res. 2007;67:10428-10435. (Pubitemid 350070818)
-
(2007)
Cancer Research
, vol.67
, Issue.21
, pp. 10428-10435
-
-
Bien, S.1
Riad, A.2
Ritter, C.A.3
Gratz, M.4
Olshausen, F.5
Westermann, D.6
Grube, M.7
Krieg, T.8
Ciecholewski, S.9
Felix, S.B.10
Staudt, A.11
Schultheiss, H.-P.12
Ewert, R.13
Volker, U.14
Tschope, C.15
Kroemer, H.K.16
-
144
-
-
33749528744
-
Microarrays coming of age in cardiovascular medicine: Standards, predictions, and biology
-
Ginsburg GS, Seo D, Frazier C. Microarrays coming of age in cardiovascular medicine: standards, predictions, and biology. J Am Coll Cardiol. 2006;48:1618-1620.
-
(2006)
J Am Coll Cardiol.
, vol.48
, pp. 1618-1620
-
-
Ginsburg, G.S.1
Seo, D.2
Frazier, C.3
-
145
-
-
34548179576
-
Role of the HER2 [Ile655Val] genetic polymorphism in tumorogenesis and in the risk of trastuzumab-related cardiotoxicity
-
DOI 10.1093/annonc/mdm181
-
Beauclair S, Formento P, Fischel JL, Lescaut W, Largillier R, Chamorey E, Hofman P, Ferrero JM, Pages G, Milano G. Role of the HER2 [Ile655Val] genetic polymorphism in tumorogenesis and in the risk of trastuzumab-related cardiotoxicity. Ann Oncol. 2007;18:1335-1341. (Pubitemid 47305006)
-
(2007)
Annals of Oncology
, vol.18
, Issue.8
, pp. 1335-1341
-
-
Beauclair, S.1
Formento, P.2
Fischel, J.L.3
Lescaut, W.4
Largillier, R.5
Chamorey, E.6
Hofman, P.7
Ferrero, J.M.8
Pages, G.9
Milano, G.10
-
146
-
-
77950815766
-
Pharmacogenetics of target genes across doxorubicin disposition pathway: A review
-
Lal S, Mahajan A, Chen WN, Chowbay B. Pharmacogenetics of target genes across doxorubicin disposition pathway: a review. Curr Drug Metab. 2010;11:115-128.
-
(2010)
Curr Drug Metab.
, vol.11
, pp. 115-128
-
-
Lal, S.1
Mahajan, A.2
Chen, W.N.3
Chowbay, B.4
-
147
-
-
34548295366
-
Genotyping the risk of anthracycline-induced cardiotoxicity
-
DOI 10.1007/s12012-007-0024-2
-
Deng S, Wojnowski L. Genotyping the risk of anthracycline-induced cardiotoxicity. Cardiovasc Toxicol. 2007;7:129-134. (Pubitemid 47339859)
-
(2007)
Cardiovascular Toxicology
, vol.7
, Issue.2
, pp. 129-134
-
-
Deng, S.1
Wojnowski, L.2
-
148
-
-
33644876141
-
NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity
-
DOI 10.1161/CIRCULATIONAHA.105.576850, PII 0000301720051213000015
-
Wojnowski L, Kulle B, Schirmer M, Schluter G, Schmidt A, Rosenberger A, Vonhof S, Bickeboller H, Toliat MR, Suk EK, Tzvetkov M, Kruger A, Seifert S, Kloess M, Hahn H, Loeffler M, Nurnberg P, Pfreundschuh M, Trumper L, Brockmoller J, Hasenfuss G. NAD (P) H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity. Circulation. 2005;112:3754-3762. (Pubitemid 43739516)
-
(2005)
Circulation
, vol.112
, Issue.24
, pp. 3754-3762
-
-
Wojnowski, L.1
Kulle, B.2
Schirmer, M.3
Schluter, G.4
Schmidt, A.5
Rosenberger, A.6
Vonhof, S.7
Bickeboller, H.8
Toliat, M.R.9
Suk, E.-K.10
Tzvetkov, M.11
Kruger, A.12
Seifert, S.13
Kloess, M.14
Hahn, H.15
Loeffler, M.16
Nurnberg, P.17
Pfreundschuh, M.18
Trumper, L.19
Brockmoller, J.20
Hasenfuss, G.21
more..
-
149
-
-
46049104446
-
Genetic polymorphisms in the carbonyl reductase 3 gene CBR3 and the NAD(P)H:quinone oxidoreductase 1 gene NQ01 in patients who developed anthracycline-related congestive heart failure after childhood cancer
-
DOI 10.1002/cncr.23534
-
Blanco JG, Leisenring WM, Gonzalez-Covarrubias VM, Kawashima TI, Davies SM, Relling MV, Robison LL, Sklar CA, Stovall M, Bhatia S. Genetic polymorphisms in the carbonyl reductase 3 gene CBR3 and the NAD (P) H: quinone oxidoreductase 1 gene NQO1 in patients who developed anthracycline-related congestive heart failure after childhood cancer. Cancer. 2008;112:2789-2795. (Pubitemid 351969225)
-
(2008)
Cancer
, vol.112
, Issue.12
, pp. 2789-2795
-
-
Blanco, J.G.1
Leisenring, W.M.2
Gonzalez-Covarrubias, V.M.3
Kawashima, T.I.4
Davies, S.M.5
Relling, M.V.6
Robison, L.L.7
Sklar, C.A.8
Stovall, M.9
Bhatia, S.10
-
150
-
-
84857466300
-
Brca2 protein deficiency exaggerates doxorubicin-induced cardiomyocyte apoptosis and cardiac failure
-
Singh KK, Shukla PC, Quan A, Desjardins JF, Lovren F, Pan Y, Garg V, Gosal S, Garg A, Szmitko PE, Schneider MD, Parker TG, Stanford WL, Leong-Poi H, Teoh H, Al-Omran M, Verma S. Brca2 protein deficiency exaggerates doxorubicin-induced cardiomyocyte apoptosis and cardiac failure. J Biol Chem. 2012;287:6604-661
-
(2012)
J Biol Chem.
, vol.287
, pp. 6604-6661
-
-
Singh, K.K.1
Shukla, P.C.2
Quan, A.3
Desjardins, J.F.4
Lovren, F.5
Pan, Y.6
Garg, V.7
Gosal, S.8
Garg, A.9
Szmitko, P.E.10
Schneider, M.D.11
Parker, T.G.12
Stanford, W.L.13
Leong-Poi, H.14
Teoh, H.15
Al-Omran, M.16
Verma, S.17
|